<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00966</drugbank-id>
  <drugbank-id>APRD01247</drugbank-id>
  <name>Telmisartan</name>
  <description>Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.</description>
  <cas-number>144701-48-4</cas-number>
  <unii>U5SYW473RQ</unii>
  <average-mass>514.6169</average-mass>
  <monoisotopic-mass>514.236876224</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A1489</ref-id>
        <pubmed-id>11558835</pubmed-id>
        <citation>Sharpe M, Jarvis B, Goa KL: Telmisartan: a review of its use in hypertension. Drugs. 2001;61(10):1501-29.</citation>
      </article>
      <article>
        <ref-id>A1490</ref-id>
        <pubmed-id>12462282</pubmed-id>
        <citation>Smith DH: Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin Ther. 2002 Oct;24(10):1484-501.</citation>
      </article>
      <article>
        <ref-id>A1491</ref-id>
        <pubmed-id>20502601</pubmed-id>
        <citation>Kumar AS, Ghosh S, Mehta GN: Efficient and improved synthesis of Telmisartan. Beilstein J Org Chem. 2010 Mar 11;6:25. doi: 10.3762/bjoc.6.25.</citation>
      </article>
      <article>
        <ref-id>A1492</ref-id>
        <pubmed-id>20448797</pubmed-id>
        <citation>Galzerano D, Capogrosso C, Di Michele S, Galzerano A, Paparello P, Lama D, Gaudio C: New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag. 2010 Mar 24;6:113-33.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Kumar AS, Ghosh S, Mehta GN: Efficient and improved synthesis of Telmisartan. Beilstein J Org Chem. 2010 Mar 11;6:25. [Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/20502601).</synthesis-reference>
  <indication>Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).</indication>
  <pharmacodynamics>Telmisartan is an orally active nonpeptide angiotensin II antagonist that acts on the AT&lt;sub&gt;1&lt;/sub&gt; receptor subtype. It has the highest affinity for the AT&lt;sub&gt;1&lt;/sub&gt; receptor among commercially available ARBS and has minimal affinity for the AT&lt;sub&gt;2&lt;/sub&gt; receptor. New studies suggest that telmisartan may also have PPAR&amp;gamma; agonistic properties that could potentially confer beneficial metabolic effects, as PPAR&amp;gamma; is a nuclear receptor that regulates specific gene transcription, and whose target genes are involved in the regulation of glucose and lipid metabolism, as well as anti-inflammatory responses. This observation is currently being explored in clinical trials. Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan works by blocking the vasoconstrictor and aldosterone secretory effects of angiotensin II.</pharmacodynamics>
  <mechanism-of-action>Telmisartan interferes with the binding of angiotensin II to the angiotensin II AT&lt;sub&gt;1&lt;/sub&gt;-receptor by binding reversibly and selectively to the receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. Telmisartan does not inhibit the angiotensin converting enzyme, other hormone receptors, or ion channels. Studies also suggest that telmisartan is a partial agonist of PPAR&amp;gamma;, which is an established target for antidiabetic drugs. This suggests that telmisartan can improve carbohydrate and lipid metabolism, as well as control insulin resistance without causing the side effects that are associated with full PPAR&amp;gamma; activators.</mechanism-of-action>
  <toxicity>Intravenous LD&lt;sub&gt;50&lt;/sub&gt; in rats is 150-200 mg/kg in males and 200 to 250 mg/kg in females. Acute oral toxicity is low: no deaths and no changes occurred in rats or dogs at 2000 mg/kg, the highest dose tested. Limited data are available with regard to overdosage in humans. The most likely manifestations of overdosage with telmisartan would be hypotension, dizziness and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.</toxicity>
  <metabolism>Minimally metabolized by conjugation to form a pharmacologically inactive acylglucuronide; the glucuronide of the parent compound is the only metabolite that has been identified in human plasma and urine. The cytochrome P450 isoenzymes are not involved in the metabolism of telmisartan.</metabolism>
  <absorption>Absolute bioavailability depends on dosage. Food slightly decreases the bioavailability (a decrease of about 6% is seen when the 40-mg dose is administered with food).</absorption>
  <half-life>Bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.</half-life>
  <protein-binding>Highly bound to plasma proteins (&amp;gt;99.5%), mainly albumin and a1-acid glycoprotein. Binding is not dose-dependent.</protein-binding>
  <route-of-elimination>Following either intravenous or oral administration of 14C-labeled telmisartan, most of the administered dose (&gt;97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).</route-of-elimination>
  <volume-of-distribution>* 500 L</volume-of-distribution>
  <clearance>* &gt;800 mL/min</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.</description>
    <direct-parent>Biphenyls and derivatives</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Biphenyls and derivatives</subclass>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzimidazoles</alternative-parent>
    <alternative-parent>Benzoic acids</alternative-parent>
    <alternative-parent>Benzoyl derivatives</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>N-substituted imidazoles</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azole</substituent>
    <substituent>Benzimidazole</substituent>
    <substituent>Benzoic acid</substituent>
    <substituent>Benzoic acid or derivatives</substituent>
    <substituent>Benzoyl</substituent>
    <substituent>Biphenyl</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Imidazole</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>N-substituted imidazole</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid</synonym>
    <synonym language="english" coder="">4'-((4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid</synonym>
    <synonym language="english" coder="">4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid</synonym>
    <synonym language="english" coder="">4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid</synonym>
    <synonym language="english" coder="inn/usan">Telmisartan</synonym>
  </synonyms>
  <products>
    <product>
      <name>Ach-telmisartan Hctz</name>
      <labeller>Accord Healthcare Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02419114</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ach-telmisartan Hctz</name>
      <labeller>Accord Healthcare Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02419122</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Telmisartan</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02393247</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-19</started-marketing-on>
      <ended-marketing-on>2018-06-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Telmisartan</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02393255</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-19</started-marketing-on>
      <ended-marketing-on>2018-06-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Telmisartan/hct</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02393263</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-02</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Telmisartan/hct</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02393271</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-02</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/001</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/002</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/003</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/004</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/005</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/006</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/007</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/008</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/009</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/010</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/011</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/012</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/013</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/014</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/015</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/016</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/017</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/018</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/019</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/020</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/021</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/022</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/023</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/024</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/025</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/026</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/027</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/028</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/029</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/030</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/031</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/032</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/033</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/034</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/035</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/036</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/037</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/038</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/039</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/040</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/041</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/042</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/043</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/044</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/045</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actelsar HCT</name>
      <labeller>Actavis Group Hf</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002676</ema-product-code>
      <ema-ma-number>EU/1/13/817/046</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Ag Telmisartan-hct</name>
      <labeller>Angita Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02484560</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ag Telmisartan-hct</name>
      <labeller>Angita Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02484579</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ag-telmisartan</name>
      <labeller>Angita Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02484536</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ag-telmisartan</name>
      <labeller>Angita Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02484544</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alembic-telmisartan</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02428245</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alembic-telmisartan</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02428253</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alembic-telmisartan/hctz</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02442884</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alembic-telmisartan/hctz</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02442892</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-telmisartan</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02420082</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-telmisartan</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02420090</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-telmisartan-amlodipine</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473453</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-telmisartan-amlodipine</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473461</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-telmisartan-amlodipine</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473488</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-telmisartan-amlodipine</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473496</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-telmisartan/hctz</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02420023</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-telmisartan/hctz</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02420031</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-telmisartan</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02453568</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-telmisartan</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02453576</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-telmisartan Hctz</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02456389</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-telmisartan Hctz</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02456397</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp Telmisartan</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02386755</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp Telmisartan</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02386763</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp Telmisartan-hct</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02389940</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp Telmisartan-hct</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02389959</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kinzalmono</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000211</ema-product-code>
      <ema-ma-number>EU/1/98/091/001</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kinzalmono</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000211</ema-product-code>
      <ema-ma-number>EU/1/98/091/002</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kinzalmono</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000211</ema-product-code>
      <ema-ma-number>EU/1/98/091/003</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kinzalmono</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000211</ema-product-code>
      <ema-ma-number>EU/1/98/091/004</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kinzalmono</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000211</ema-product-code>
      <ema-ma-number>EU/1/98/091/005</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kinzalmono</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000211</ema-product-code>
      <ema-ma-number>EU/1/98/091/006</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kinzalmono</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000211</ema-product-code>
      <ema-ma-number>EU/1/98/091/007</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kinzalmono</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000211</ema-product-code>
      <ema-ma-number>EU/1/98/091/008</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kinzalmono</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000211</ema-product-code>
      <ema-ma-number>EU/1/98/091/009</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kinzalmono</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000211</ema-product-code>
      <ema-ma-number>EU/1/98/091/010</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kinzalmono</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000211</ema-product-code>
      <ema-ma-number>EU/1/98/091/011</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kinzalmono</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000211</ema-product-code>
      <ema-ma-number>EU/1/98/091/012</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kinzalmono</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000211</ema-product-code>
      <ema-ma-number>EU/1/98/091/013</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Kinzalmono</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000211</ema-product-code>
      <ema-ma-number>EU/1/98/091/014</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mar-telmisartan</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02448297</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mar-telmisartan</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02448300</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/001</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/002</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/003</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/004</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/005</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/006</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/007</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/008</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/009</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/010</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/011</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/012</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/013</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/014</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/015</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/016</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/017</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/018</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/019</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/020</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/021</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000209</ema-product-code>
      <ema-ma-number>EU/1/98/090/022</ema-ma-number>
      <started-marketing-on>1998-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6193</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020850</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4539</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020850</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4605</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020850</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim Promeco s.a. De c.v.</labeller>
      <ndc-id/>
      <ndc-product-code>64674-039</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-01</started-marketing-on>
      <ended-marketing-on>2013-05-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020850</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim Promeco s.a. De c.v.</labeller>
      <ndc-id/>
      <ndc-product-code>64674-040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-01</started-marketing-on>
      <ended-marketing-on>2013-05-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020850</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim Promeco s.a. De c.v.</labeller>
      <ndc-id/>
      <ndc-product-code>64674-041</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-01</started-marketing-on>
      <ended-marketing-on>2013-05-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020850</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Lake Erie Medical &amp;Surgical Supply Dba Quality Care Products Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-298</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-15</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020850</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0039</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020850</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020850</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0041</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020850</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis 40mg Tab</name>
      <labeller>Boehringer Ingelheim (Canada) Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240769</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Micardis 80mg Tab</name>
      <labeller>Boehringer Ingelheim (Canada) Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240770</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Micardis HCT</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5418</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021162</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis HCT</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4540</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021162</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis HCT</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5297</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021162</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis HCT</name>
      <labeller>Lake Erie Medical &amp;Surgical Supply Dba Quality Care Products Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-299</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-15</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021162</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis HCT</name>
      <labeller>Lake Erie Medical &amp;Surgical Supply Dba Quality Care Products Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-300</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-15</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021162</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis HCT</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0043</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021162</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis HCT</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0044</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021162</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis HCT</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0042</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021162</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micardis Plus</name>
      <labeller>Boehringer Ingelheim (Canada) Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02244344</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Micardis Plus</name>
      <labeller>Boehringer Ingelheim (Canada) Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02318709</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-telmisartan</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02486369</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-telmisartan</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02486377</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-telmisartan</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02376717</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-10</started-marketing-on>
      <ended-marketing-on>2018-08-15</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-telmisartan</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02376725</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-10</started-marketing-on>
      <ended-marketing-on>2018-08-15</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-telmisartan Hctz</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02373564</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-07</started-marketing-on>
      <ended-marketing-on>2017-05-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-telmisartan Hctz</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02373572</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-07</started-marketing-on>
      <ended-marketing-on>2017-05-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-telmisartan</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02388723</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-telmisartan</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02388731</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-telmisartan Hctz</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02388758</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-telmisartan Hctz</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02388782</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pendo-telmisartan</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02427281</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pendo-telmisartan</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02427303</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pendo-telmisartan-hctz</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02427230</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pendo-telmisartan-hctz</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02427249</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-telmisartan</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391236</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-08-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-telmisartan</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391244</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-08-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-telmisartan-hctz</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401665</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-telmisartan-hctz</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401673</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/001</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/002</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/003</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/004</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/005</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/006</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/007</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/008</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/009</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/010</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/011</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/012</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/013</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/014</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/015</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/016</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/017</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/018</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/019</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/020</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/021</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pritor</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000210</ema-product-code>
      <ema-ma-number>EU/1/98/089/022</ema-ma-number>
      <started-marketing-on>1998-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Ran-telmisartan</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02395401</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-telmisartan</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02395428</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-telmisartan Hctz</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02396238</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-telmisartan Hctz</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02396246</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Telmisartan</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02375958</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Telmisartan</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02375966</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Telmisartan HCT</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02393557</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Telmisartan HCT</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02393565</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Septa-telmisartan</name>
      <labeller>Septa Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02440741</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Septa-telmisartan</name>
      <labeller>Septa Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02440768</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-087</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-06</started-marketing-on>
      <ended-marketing-on>2014-07-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-088</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-06</started-marketing-on>
      <ended-marketing-on>2014-07-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-089</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-06</started-marketing-on>
      <ended-marketing-on>2014-07-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-2921</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-15</started-marketing-on>
      <ended-marketing-on>2018-05-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202397</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5914</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-25</started-marketing-on>
      <ended-marketing-on>2017-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5915</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-25</started-marketing-on>
      <ended-marketing-on>2017-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5916</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-25</started-marketing-on>
      <ended-marketing-on>2017-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-283</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207882</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-284</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207882</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-285</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207882</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-7230</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203867</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Camber Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>31722-802</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205901</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Camber Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>31722-803</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205901</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Camber Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>31722-804</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205901</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Mesource Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>45865-841</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-27</started-marketing-on>
      <ended-marketing-on>2016-04-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203325</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65841-804</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203325</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65841-805</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203325</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65841-806</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203325</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Zydus Pharmaceuticals Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-471</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203325</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Zydus Pharmaceuticals Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-472</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203325</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Zydus Pharmaceuticals Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-473</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203325</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0875</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203325</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-0542</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020850</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-0543</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020850</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-0544</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020850</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-2920</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202397</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-2921</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202397</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-2922</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202397</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>medsource pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>45865-836</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3292</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-08</started-marketing-on>
      <ended-marketing-on>2019-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3293</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-08</started-marketing-on>
      <ended-marketing-on>2019-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3294</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-08</started-marketing-on>
      <ended-marketing-on>2019-10-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-439</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204164</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-440</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204164</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-441</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204164</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4937</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205150</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Hisun Pharmaceuticals Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42658-135</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207843</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Hisun Pharmaceuticals Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42658-136</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207843</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Hisun Pharmaceuticals Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42658-137</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207843</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-087</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-088</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-089</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-482</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205150</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-483</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205150</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-484</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205150</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Cadila Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>71209-049</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208605</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Cadila Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>71209-050</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208605</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Cadila Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>71209-051</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208605</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-608</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-609</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-610</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-867</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-868</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-869</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-199</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-200</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-156</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203171</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-157</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203171</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-158</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203171</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>AvKARE, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-790</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204415</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>AvKARE, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-791</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204415</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>AvKARE, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-792</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204415</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>53746-291</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204415</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>53746-292</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204415</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>53746-293</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204415</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Micro Labs Limited</labeller>
      <ndc-id/>
      <ndc-product-code>42571-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207016</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Micro Labs Limited</labeller>
      <ndc-id/>
      <ndc-product-code>42571-227</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207016</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Micro Labs Limited</labeller>
      <ndc-id/>
      <ndc-product-code>42571-228</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207016</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-951</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205150</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5372</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203867</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203867</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5378</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203867</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-291</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204415</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-292</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204415</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-293</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204415</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02388944</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02388952</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Sivem Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02390345</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Sivem Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02390353</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02395223</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02395231</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02432900</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02432897</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-793</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201586</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-794</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201586</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-795</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201586</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-796</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201586</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-1075</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202516</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-1076</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202516</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-1077</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202516</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-1078</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202516</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-196</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201586</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-197</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201586</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-198</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201586</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-199</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201586</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-184</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205234</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-185</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205234</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-186</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205234</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-187</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205234</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-346</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202517</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-345</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202517</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-344</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202517</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Amlodipine</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-343</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202517</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5926</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-27</started-marketing-on>
      <ended-marketing-on>2017-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203010</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5927</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-27</started-marketing-on>
      <ended-marketing-on>2017-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203010</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5928</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-27</started-marketing-on>
      <ended-marketing-on>2017-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203010</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Solco Healthcare Llc</labeller>
      <ndc-id/>
      <ndc-product-code>43547-441</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA209028</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Solco Healthcare Llc</labeller>
      <ndc-id/>
      <ndc-product-code>43547-442</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA209028</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Solco Healthcare Llc</labeller>
      <ndc-id/>
      <ndc-product-code>43547-443</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA209028</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TELMISARTAN and HYDROCHLOROTHIAZIDE</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-128</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204169</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TELMISARTAN and HYDROCHLOROTHIAZIDE</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-129</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204169</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TELMISARTAN and HYDROCHLOROTHIAZIDE</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204169</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-2901</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-06</started-marketing-on>
      <ended-marketing-on>2016-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091648</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-2902</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-06</started-marketing-on>
      <ended-marketing-on>2016-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091648</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-2903</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-06</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091648</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TELMISARTAN and HYDROCHLOROTHIAZIDE</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-7546</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204169</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-0545</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021162</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-0546</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021162</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-0547</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021162</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-7854</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203010</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-840</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202544</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-841</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202544</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-842</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202544</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-976</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA208727</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-977</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA208727</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-978</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA208727</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-209</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203010</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203010</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203010</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-195</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091351</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-193</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091351</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-194</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091351</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-513</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204221</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-514</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204221</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-515</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204221</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1123</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204221</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1124</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204221</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1125</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204221</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide 40 mg/12.5 mg</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-209</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203010</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide 80 mg/12.5 mg</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203010</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorothiazide 80 mg/25 mg</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203010</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorthiazide</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201192</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorthiazide</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-160</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201192</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan and Hydrochlorthiazide</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-161</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201192</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Telmisartan Hctz</name>
      <labeller>Sivem Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02390302</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan Hctz</name>
      <labeller>Sivem Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02390310</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan Tablets</name>
      <labeller>Accord Healthcare Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02407485</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan Tablets</name>
      <labeller>Accord Healthcare Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02407493</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/001</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/002</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/003</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/004</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/005</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/006</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/007</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/008</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/009</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/010</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/011</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/012</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/013</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/014</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/015</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/016</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/017</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/018</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/019</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/020</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/021</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/022</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/023</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/024</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/025</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/026</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/027</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/028</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/029</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/030</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/031</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/032</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/033</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/034</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/035</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/036</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/037</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/038</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/039</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/040</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/041</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/042</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/043</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/044</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/045</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/046</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/047</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/048</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/049</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/050</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/051</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/052</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/053</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/054</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/055</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/056</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/057</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/058</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/059</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/060</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/061</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001146</ema-product-code>
      <ema-ma-number>EU/1/09/610/062</ema-ma-number>
      <started-marketing-on>2010-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/001</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/002</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/003</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/004</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/005</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/006</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/007</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/008</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/009</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/010</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/011</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/012</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/013</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/014</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/015</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/016</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/017</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/018</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/019</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/020</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/021</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/022</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/023</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/024</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/025</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/026</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/027</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/028</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/029</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/030</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/031</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/032</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/033</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/034</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/035</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/036</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/037</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/038</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/039</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/040</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/041</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/042</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/043</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/044</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/045</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/046</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/047</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/048</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/049</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/050</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/051</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/052</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/053</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/054</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/055</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/056</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/057</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/058</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/059</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/060</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/061</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/062</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/063</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/064</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan Teva Pharma</name>
      <labeller>Teva B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002511</ema-product-code>
      <ema-ma-number>EU/1/11/719/065</ema-ma-number>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Telmisartan-hctz</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02395525</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan-hctz</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02395533</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan-hctz</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02433214</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan-hctz</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02433222</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan/hctz</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02395355</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telmisartan/hctz</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02395363</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-telmisartan</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02320177</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-telmisartan</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02320185</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-telmisartan Hctz</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02330288</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-telmisartan Hctz</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02379252</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/001</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/002</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/003</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/004</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/005</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/006</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/007</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/008</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/009</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/010</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/011</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/012</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/013</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/014</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/015</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/016</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/017</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/018</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/019</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/020</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/021</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/022</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/023</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/024</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/025</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/026</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/027</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/028</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/029</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/030</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/031</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/032</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolucombi</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002549</ema-product-code>
      <ema-ma-number>EU/1/13/821/033</ema-ma-number>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/001</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/002</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/003</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/004</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/005</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/006</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/007</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/008</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/009</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/010</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/011</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/012</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/013</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/014</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/015</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/016</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/017</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/018</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/019</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/020</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/021</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/022</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/023</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Tolura</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001196</ema-product-code>
      <ema-ma-number>EU/1/10/632/024</ema-ma-number>
      <started-marketing-on>2010-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>80 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/001</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/002</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/003</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/004</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/005</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/006</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/007</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/008</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/009</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/010</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/011</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/012</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/013</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/014</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/015</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/016</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/017</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/018</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/019</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/020</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/021</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/022</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/023</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/024</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/025</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/026</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/027</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001224</ema-product-code>
      <ema-ma-number>EU/1/10/648/028</ema-ma-number>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0124</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, multilayer</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022401</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0125</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, multilayer</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022401</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0126</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, multilayer</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022401</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, multilayer</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022401</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim (Canada) Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371022</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim (Canada) Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371030</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim (Canada) Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371049</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Twynsta</name>
      <labeller>Boehringer Ingelheim (Canada) Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371057</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Van-telmisartan</name>
      <labeller>Vanc Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02434164</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-10</started-marketing-on>
      <ended-marketing-on>2019-08-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Van-telmisartan</name>
      <labeller>Vanc Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02434172</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-10</started-marketing-on>
      <ended-marketing-on>2019-08-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Van-telmisartan-hctz</name>
      <labeller>Vanc Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02434067</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Van-telmisartan-hctz</name>
      <labeller>Vanc Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02434075</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Kinzalmono</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Kinzalmono</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Kinzalmono</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Kinzalmono</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Kinzalmono</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Kinzalmono</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Kinzalmono</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Kinzalmono</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Kinzalmono</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Kinzalmono</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Kinzalmono</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Kinzalmono</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Kinzalmono</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Kinzalmono</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pritor</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Teva Pharma</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolura</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Actelsar HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Tolucombi</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>TELMISARTAN and HYDROCHLOROTHIAZIDE</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>TELMISARTAN and HYDROCHLOROTHIAZIDE</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>TELMISARTAN and HYDROCHLOROTHIAZIDE</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>TELMISARTAN and HYDROCHLOROTHIAZIDE</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide 40 mg/12.5 mg</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide 80 mg/12.5 mg</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide 80 mg/25 mg</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorthiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorthiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorthiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan and Hydrochlorothiazide</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis 40mg Tab</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis 80mg Tab</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis Plus</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Micardis Plus</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Teva-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Teva-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Teva-telmisartan Hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Twynsta</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Teva-telmisartan Hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>PMS-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>PMS-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Act Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Act Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Telmisartan HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Telmisartan HCT</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan/hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan/hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan-hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan-hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>PMS-telmisartan-hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>PMS-telmisartan-hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Apo-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Apo-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan-hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Jamp Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Jamp Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Jamp Telmisartan-hct</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Jamp Telmisartan-hct</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pendo-telmisartan-hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pendo-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pendo-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Alembic-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Alembic-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Van-telmisartan-hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Van-telmisartan-hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Tablets</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Tablets</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Ach-telmisartan Hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Ach-telmisartan Hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Apo-telmisartan/hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Apo-telmisartan/hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Mar-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Mar-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Alembic-telmisartan/hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Alembic-telmisartan/hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan-hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Septa-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Septa-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-telmisartan Hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-telmisartan Hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-telmisartan Hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-telmisartan Hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Ran-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Ran-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Ran-telmisartan Hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Ran-telmisartan Hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Act Telmisartan/hct</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Act Telmisartan/hct</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Van-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Van-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Auro-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Auro-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Auro-telmisartan Hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Auro-telmisartan Hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Apo-telmisartan-amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Apo-telmisartan-amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Apo-telmisartan-amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Apo-telmisartan-amlodipine</name>
      <ingredients>Amlodipine + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Telmisartan Hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Pendo-telmisartan-hctz</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Ag-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Ag-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Ag Telmisartan-hct</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Ag Telmisartan-hct</name>
      <ingredients>Hydrochlorothiazide + Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Mint-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
    <mixture>
      <name>Mint-telmisartan</name>
      <ingredients>Telmisartan</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>A-S Medication Solutions LLC</name>
      <url>http://orders.a-smeds.com</url>
    </packager>
    <packager>
      <name>Boehringer Ingelheim Ltd.</name>
      <url>http://www.boehringer-ingelheim.com</url>
    </packager>
    <packager>
      <name>Lake Erie Medical and Surgical Supply</name>
      <url/>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Boehringer ingelheim</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Micardis 40 mg tablet</description>
      <cost currency="USD">2.24</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Micardis 80 mg tablet</description>
      <cost currency="USD">2.24</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Micardis 20 mg tablet</description>
      <cost currency="USD">3.29</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Micardis hct 40-12.5 mg tablet</description>
      <cost currency="USD">3.29</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Micardis hct 80-12.5 mg tablet</description>
      <cost currency="USD">3.29</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Micardis hct 80-25 mg tablet</description>
      <cost currency="USD">3.29</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Micardis 30 20 mg tablet Box</description>
      <cost currency="USD">99.7</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Micardis HCT 30 80-25 mg tablet Box</description>
      <cost currency="USD">100.48</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Micardis 30 80 mg tablet Box</description>
      <cost currency="USD">103.92</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Micardis HCT 30 80-12.5 mg tablet Box</description>
      <cost currency="USD">106.18</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Micardis HCT 30 40-12.5 mg tablet Box</description>
      <cost currency="USD">106.34</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Micardis 30 40 mg tablet Box</description>
      <cost currency="USD">110.11</cost>
      <unit>box</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Agents Acting on the Renin-Angiotensin System</category>
      <mesh-id/>
    </category>
    <category>
      <category>Agents causing angioedema</category>
      <mesh-id/>
    </category>
    <category>
      <category>Agents causing hyperkalemia</category>
      <mesh-id/>
    </category>
    <category>
      <category>Angiotensin 2 Receptor Blocker</category>
      <mesh-id/>
    </category>
    <category>
      <category>Angiotensin II receptor blockers (ARBs) and calcium channel blockers</category>
      <mesh-id/>
    </category>
    <category>
      <category>Angiotensin II receptor blockers (ARBs) and diuretics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Angiotensin II receptor blockers (ARBs), plain</category>
      <mesh-id/>
    </category>
    <category>
      <category>Angiotensin II Type 1 Receptor Blockers</category>
      <mesh-id>D047228</mesh-id>
    </category>
    <category>
      <category>Angiotensin II Type 2 Receptor Blockers</category>
      <mesh-id>D057912</mesh-id>
    </category>
    <category>
      <category>Angiotensin Receptor Antagonists</category>
      <mesh-id>D057911</mesh-id>
    </category>
    <category>
      <category>Antihypertensive Agents</category>
      <mesh-id>D000959</mesh-id>
    </category>
    <category>
      <category>BCRP/ABCG2 Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Benzene Derivatives</category>
      <mesh-id>D001555</mesh-id>
    </category>
    <category>
      <category>Benzimidazoles</category>
      <mesh-id>D001562</mesh-id>
    </category>
    <category>
      <category>Biphenyl Compounds</category>
      <mesh-id>D001713</mesh-id>
    </category>
    <category>
      <category>BSEP/ABCB11 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cardiovascular Agents</category>
      <mesh-id>D002317</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C19 Inhibitors</category>
      <mesh-id>D065689</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C19 inhibitors (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inhibitors</category>
      <mesh-id>D065607</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Hypotensive Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>P-glycoprotein inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>UGT1A3 substrates</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>20 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>40 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>80 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>20 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>40 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>80 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, multilayer</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="C09DB04">
      <level code="C09DB">Angiotensin II receptor blockers (ARBs) and calcium channel blockers</level>
      <level code="C09D">ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS</level>
      <level code="C09">AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</level>
      <level code="C">CARDIOVASCULAR SYSTEM</level>
    </atc-code>
    <atc-code code="C09CA07">
      <level code="C09CA">Angiotensin II receptor blockers (ARBs), plain</level>
      <level code="C09C">ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN</level>
      <level code="C09">AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</level>
      <level code="C">CARDIOVASCULAR SYSTEM</level>
    </atc-code>
    <atc-code code="C09DA07">
      <level code="C09DA">Angiotensin II receptor blockers (ARBs) and diuretics</level>
      <level code="C09D">ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS</level>
      <level code="C09">AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</level>
      <level code="C">CARDIOVASCULAR SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>24:32.08</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>3vn2</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00966.pdf?1265922811</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00966.pdf?1265922747</msds>
  <patents>
    <patent>
      <number>5591762</number>
      <country>United States</country>
      <approved>1997-01-07</approved>
      <expires>2014-01-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2060624</number>
      <country>Canada</country>
      <approved>1999-12-21</approved>
      <expires>2012-02-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6358986</number>
      <country>United States</country>
      <approved>2002-03-19</approved>
      <expires>2020-01-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7998953</number>
      <country>United States</country>
      <approved>2011-08-16</approved>
      <expires>2020-06-06</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8003679</number>
      <country>United States</country>
      <approved>2011-08-23</approved>
      <expires>2022-10-06</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The risk or severity of orthostatic hypotension and syncope can be increased when Telmisartan is combined with Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01235</drugbank-id>
      <name>Levodopa</name>
      <description>The risk or severity of hypotension and orthostatic hypotension can be increased when Telmisartan is combined with Levodopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>Telmisartan may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>Troglitazone may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>Reserpine may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>Progesterone may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>Chlorpromazine may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>Cimetidine may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>Bosentan may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>Vinblastine may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>Tamoxifen may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00845</drugbank-id>
      <name>Clofazimine</name>
      <description>Clofazimine may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>Tipranavir may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>Ethinylestradiol may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>Glyburide may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>Ketoconazole may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01586</drugbank-id>
      <name>Ursodeoxycholic acid</name>
      <description>Ursodeoxycholic acid may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02659</drugbank-id>
      <name>Cholic Acid</name>
      <description>Cholic Acid may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02703</drugbank-id>
      <name>Fusidic acid</name>
      <description>Fusidic acid may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>Simeprevir may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>Lenvatinib may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12070</drugbank-id>
      <name>Letermovir</name>
      <description>Letermovir may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14057</drugbank-id>
      <name>Valinomycin</name>
      <description>Valinomycin may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00346</drugbank-id>
      <name>Alfuzosin</name>
      <description>Alfuzosin may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09026</drugbank-id>
      <name>Aliskiren</name>
      <description>The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01143</drugbank-id>
      <name>Amifostine</name>
      <description>Telmisartan may increase the hypotensive activities of Amifostine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>Diazoxide may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Drospirenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06294</drugbank-id>
      <name>Semuloparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>Methyclothiazide may increase the hypotensive and Electrolyte Disturbance activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>Bendroflumethiazide may increase the hypotensive and Electrolyte Disturbance activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>Benzthiazide may increase the hypotensive and Electrolyte Disturbance activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>Cyclothiazide may increase the hypotensive and Electrolyte Disturbance activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>Hydroflumethiazide may increase the hypotensive and Electrolyte Disturbance activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>Chlorothiazide may increase the hypotensive and Electrolyte Disturbance activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>Trichlormethiazide may increase the hypotensive and Electrolyte Disturbance activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>Polythiazide may increase the hypotensive and Electrolyte Disturbance activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>Mebutizide may increase the hypotensive and Electrolyte Disturbance activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>Cyclopenthiazide may increase the hypotensive and Electrolyte Disturbance activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>The serum concentration of Lithium cation can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14507</drugbank-id>
      <name>Lithium citrate</name>
      <description>The serum concentration of Lithium citrate can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14509</drugbank-id>
      <name>Lithium carbonate</name>
      <description>The serum concentration of Lithium carbonate can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14506</drugbank-id>
      <name>Lithium hydroxide</name>
      <description>The serum concentration of Lithium hydroxide can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00422</drugbank-id>
      <name>Methylphenidate</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06701</drugbank-id>
      <name>Dexmethylphenidate</name>
      <description>Dexmethylphenidate may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>Telmisartan may increase the hypotensive activities of Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>Pentoxifylline may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>Telmisartan may increase the hypotensive activities of Rituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00035</drugbank-id>
      <name>Desmopressin</name>
      <description>Desmopressin may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>Phentermine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00211</drugbank-id>
      <name>Midodrine</name>
      <description>Midodrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00221</drugbank-id>
      <name>Isoetharine</name>
      <description>Isoetharine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00228</drugbank-id>
      <name>Enflurane</name>
      <description>Enflurane may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>Ziprasidone may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00247</drugbank-id>
      <name>Methysergide</name>
      <description>Methysergide may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>Atomoxetine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00292</drugbank-id>
      <name>Etomidate</name>
      <description>Etomidate may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>Zolmitriptan may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>Dihydroergotamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>Protriptyline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00353</drugbank-id>
      <name>Methylergometrine</name>
      <description>Methylergometrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00368</drugbank-id>
      <name>Norepinephrine</name>
      <description>Norepinephrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>Mirtazapine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00388</drugbank-id>
      <name>Phenylephrine</name>
      <description>Phenylephrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00397</drugbank-id>
      <name>Phenylpropanolamine</name>
      <description>Phenylpropanolamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>Promazine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>Droperidol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>Buspirone may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>Nortriptyline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>Amoxapine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00561</drugbank-id>
      <name>Doxapram</name>
      <description>Doxapram may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00589</drugbank-id>
      <name>Lisuride</name>
      <description>Lisuride may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00610</drugbank-id>
      <name>Metaraminol</name>
      <description>Metaraminol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>Trazodone may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>Epinephrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>Ergotamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00699</drugbank-id>
      <name>Nicergoline</name>
      <description>Nicergoline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00723</drugbank-id>
      <name>Methoxamine</name>
      <description>Methoxamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00777</drugbank-id>
      <name>Propiomazine</name>
      <description>Propiomazine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>Alfentanil may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>Fentanyl may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00816</drugbank-id>
      <name>Orciprenaline</name>
      <description>Orciprenaline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00830</drugbank-id>
      <name>Phenmetrazine</name>
      <description>Phenmetrazine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00841</drugbank-id>
      <name>Dobutamine</name>
      <description>Dobutamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>Pseudoephedrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>Benzphetamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00867</drugbank-id>
      <name>Ritodrine</name>
      <description>Ritodrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>Terbutaline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00901</drugbank-id>
      <name>Bitolterol</name>
      <description>Bitolterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>Almotriptan may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00935</drugbank-id>
      <name>Oxymetazoline</name>
      <description>Oxymetazoline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>Diethylpropion may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>Salmeterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00952</drugbank-id>
      <name>Naratriptan</name>
      <description>Naratriptan may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00953</drugbank-id>
      <name>Rizatriptan</name>
      <description>Rizatriptan may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>Formoterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00988</drugbank-id>
      <name>Dopamine</name>
      <description>Dopamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>Frovatriptan may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01001</drugbank-id>
      <name>Salbutamol</name>
      <description>Salbutamol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>Methoxyflurane may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01049</drugbank-id>
      <name>Ergoloid mesylate</name>
      <description>Ergoloid mesylate may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01064</drugbank-id>
      <name>Isoprenaline</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01102</drugbank-id>
      <name>Arbutamine</name>
      <description>Arbutamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01126</drugbank-id>
      <name>Dutasteride</name>
      <description>Dutasteride may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Desipramine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01186</drugbank-id>
      <name>Pergolide</name>
      <description>Pergolide may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01216</drugbank-id>
      <name>Finasteride</name>
      <description>Finasteride may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergometrine</name>
      <description>Ergometrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>Lisdexamfetamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>Arformoterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>Fenoterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01291</drugbank-id>
      <name>Pirbuterol</name>
      <description>Pirbuterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01363</drugbank-id>
      <name>Ephedra sinica root</name>
      <description>Ephedra sinica root may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01364</drugbank-id>
      <name>Ephedrine</name>
      <description>Ephedrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>Mephentermine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01366</drugbank-id>
      <name>Procaterol</name>
      <description>Procaterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01392</drugbank-id>
      <name>Yohimbine</name>
      <description>Yohimbine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>Methotrimeprazine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01407</drugbank-id>
      <name>Clenbuterol</name>
      <description>Clenbuterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01408</drugbank-id>
      <name>Bambuterol</name>
      <description>Bambuterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>MMDA may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>Midomafetamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01467</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylamphetamine</name>
      <description>2,5-Dimethoxy-4-ethylamphetamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01472</drugbank-id>
      <name>4-Methoxyamphetamine</name>
      <description>4-Methoxyamphetamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>4-Bromo-2,5-dimethoxyamphetamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>Tenamfetamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01556</drugbank-id>
      <name>Chlorphentermine</name>
      <description>Chlorphentermine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>Dextroamphetamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>Metamfetamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01579</drugbank-id>
      <name>Phendimetrazine</name>
      <description>Phendimetrazine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>Solifenacin may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01608</drugbank-id>
      <name>Periciazine</name>
      <description>Periciazine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>Acepromazine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01622</drugbank-id>
      <name>Thioproperazine</name>
      <description>Thioproperazine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>Zuclopenthixol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04581</drugbank-id>
      <name>1-benzylimidazole</name>
      <description>1-benzylimidazole may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04829</drugbank-id>
      <name>Lysergic acid diethylamide</name>
      <description>Lysergic acid diethylamide may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>Amineptine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>Dronedarone may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04908</drugbank-id>
      <name>Flibanserin</name>
      <description>Flibanserin may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>Iloperidone may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05395</drugbank-id>
      <name>Amibegron</name>
      <description>Amibegron may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05562</drugbank-id>
      <name>Naluzotan</name>
      <description>Naluzotan may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06016</drugbank-id>
      <name>Cariprazine</name>
      <description>Cariprazine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>Mianserin may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>Pizotifen may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06190</drugbank-id>
      <name>Solabegron</name>
      <description>Solabegron may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>Asenapine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06262</drugbank-id>
      <name>Droxidopa</name>
      <description>Droxidopa may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06678</drugbank-id>
      <name>Esmirtazapine</name>
      <description>Esmirtazapine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06690</drugbank-id>
      <name>Nitrous oxide</name>
      <description>Nitrous oxide may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06694</drugbank-id>
      <name>Xylometazoline</name>
      <description>Xylometazoline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06706</drugbank-id>
      <name>Isometheptene</name>
      <description>Isometheptene may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06707</drugbank-id>
      <name>Levonordefrin</name>
      <description>Levonordefrin may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06711</drugbank-id>
      <name>Naphazoline</name>
      <description>Naphazoline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06764</drugbank-id>
      <name>Tetryzoline</name>
      <description>Tetryzoline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08810</drugbank-id>
      <name>Cinitapride</name>
      <description>Cinitapride may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>Lurasidone may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08841</drugbank-id>
      <name>Tyramine</name>
      <description>Tyramine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08925</drugbank-id>
      <name>Adrafinil</name>
      <description>Adrafinil may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>Ifenprodil may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08957</drugbank-id>
      <name>Hexoprenaline</name>
      <description>Hexoprenaline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08985</drugbank-id>
      <name>Etilefrine</name>
      <description>Etilefrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>Dimetacrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>Butriptyline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>Tedizolid phosphate may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>Cannabidiol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09080</drugbank-id>
      <name>Olodaterol</name>
      <description>Olodaterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>Vilanterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>Brexpiprazole may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>Dosulepin may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09202</drugbank-id>
      <name>Cirazoline</name>
      <description>Cirazoline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09203</drugbank-id>
      <name>Synephrine</name>
      <description>Synephrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09205</drugbank-id>
      <name>Moxisylyte</name>
      <description>Moxisylyte may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>Tianeptine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>Oxaprotiline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09480</drugbank-id>
      <name>Iofetamine I-123</name>
      <description>Iofetamine I-123 may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11124</drugbank-id>
      <name>Racepinephrine</name>
      <description>Racepinephrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11273</drugbank-id>
      <name>Dihydroergocornine</name>
      <description>Dihydroergocornine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11278</drugbank-id>
      <name>DL-Methylephedrine</name>
      <description>DL-Methylephedrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11373</drugbank-id>
      <name>Amitraz</name>
      <description>Amitraz may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11428</drugbank-id>
      <name>Medetomidine</name>
      <description>Medetomidine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11477</drugbank-id>
      <name>Xylazine</name>
      <description>Xylazine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11481</drugbank-id>
      <name>Atipamezole</name>
      <description>Atipamezole may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11541</drugbank-id>
      <name>Ractopamine</name>
      <description>Ractopamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11543</drugbank-id>
      <name>Romifidine</name>
      <description>Romifidine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11556</drugbank-id>
      <name>Detomidine</name>
      <description>Detomidine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11587</drugbank-id>
      <name>Etafedrine</name>
      <description>Etafedrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11755</drugbank-id>
      <name>Tetrahydrocannabivarin</name>
      <description>Tetrahydrocannabivarin may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11871</drugbank-id>
      <name>PF-00610355</name>
      <description>PF-00610355 may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>Ritobegron may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12100</drugbank-id>
      <name>Abediterol</name>
      <description>Abediterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12248</drugbank-id>
      <name>Tulobuterol</name>
      <description>Tulobuterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>Propiverine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12313</drugbank-id>
      <name>Dopexamine</name>
      <description>Dopexamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12361</drugbank-id>
      <name>Piclozotan</name>
      <description>Piclozotan may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12371</drugbank-id>
      <name>Siponimod</name>
      <description>Siponimod may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12551</drugbank-id>
      <name>Idazoxan</name>
      <description>Idazoxan may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12779</drugbank-id>
      <name>Higenamine</name>
      <description>Higenamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12846</drugbank-id>
      <name>Reproterol</name>
      <description>Reproterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12927</drugbank-id>
      <name>Theodrenaline</name>
      <description>Theodrenaline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>Opipramol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13064</drugbank-id>
      <name>Tramazoline</name>
      <description>Tramazoline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13108</drugbank-id>
      <name>Mephedrone</name>
      <description>Mephedrone may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>Amitriptylinoxide may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13139</drugbank-id>
      <name>Levosalbutamol</name>
      <description>Levosalbutamol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>Dibenzepin may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>Quinupramine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13251</drugbank-id>
      <name>Octopamine</name>
      <description>Octopamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13316</drugbank-id>
      <name>Ibopamine</name>
      <description>Ibopamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13323</drugbank-id>
      <name>Trichloroethylene</name>
      <description>Trichloroethylene may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13341</drugbank-id>
      <name>Fenozolone</name>
      <description>Fenozolone may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13378</drugbank-id>
      <name>Norfenefrine</name>
      <description>Norfenefrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>Melitracen may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13385</drugbank-id>
      <name>Dihydroergocryptine</name>
      <description>Dihydroergocryptine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13398</drugbank-id>
      <name>Oxyfedrine</name>
      <description>Oxyfedrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13399</drugbank-id>
      <name>Terguride</name>
      <description>Terguride may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>Lofepramine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13453</drugbank-id>
      <name>Xenon</name>
      <description>Xenon may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>Iprindole may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13510</drugbank-id>
      <name>Buflomedil</name>
      <description>Buflomedil may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13520</drugbank-id>
      <name>Metergoline</name>
      <description>Metergoline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13559</drugbank-id>
      <name>Rimiterol</name>
      <description>Rimiterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>Diethyl ether may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13624</drugbank-id>
      <name>Methoxyphenamine</name>
      <description>Methoxyphenamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13692</drugbank-id>
      <name>Tretoquinol</name>
      <description>Tretoquinol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13703</drugbank-id>
      <name>Gepefrine</name>
      <description>Gepefrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13777</drugbank-id>
      <name>Prenalterol</name>
      <description>Prenalterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13781</drugbank-id>
      <name>Xamoterol</name>
      <description>Xamoterol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>Imipramine oxide may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13852</drugbank-id>
      <name>Mefenorex</name>
      <description>Mefenorex may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13917</drugbank-id>
      <name>Deoxyepinephrine</name>
      <description>Deoxyepinephrine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>2,5-Dimethoxy-4-ethylthioamphetamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14010</drugbank-id>
      <name>5-methoxy-N,N-dimethyltryptamine</name>
      <description>5-methoxy-N,N-dimethyltryptamine may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14754</drugbank-id>
      <name>Solriamfetol</name>
      <description>Solriamfetol may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02032</drugbank-id>
      <name>1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid</name>
      <description>1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>The risk or severity of adverse effects can be increased when Telmisartan is combined with Ramipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>The serum concentration of Acetyldigitoxin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>The serum concentration of Deslanoside can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>The serum concentration of Ouabain can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The serum concentration of Digitoxin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>The serum concentration of Oleandrin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13240</drugbank-id>
      <name>Cymarin</name>
      <description>The serum concentration of Cymarin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13307</drugbank-id>
      <name>Proscillaridin</name>
      <description>The serum concentration of Proscillaridin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13467</drugbank-id>
      <name>Lanatoside C</name>
      <description>The serum concentration of Lanatoside C can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13537</drugbank-id>
      <name>Gitoformate</name>
      <description>The serum concentration of Gitoformate can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13756</drugbank-id>
      <name>Peruvoside</name>
      <description>The serum concentration of Peruvoside can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09282</drugbank-id>
      <name>Molsidomine</name>
      <description>Molsidomine may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00287</drugbank-id>
      <name>Travoprost</name>
      <description>Travoprost may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00521</drugbank-id>
      <name>Carteolol</name>
      <description>Carteolol may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00869</drugbank-id>
      <name>Dorzolamide</name>
      <description>Dorzolamide may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00905</drugbank-id>
      <name>Bimatoprost</name>
      <description>Bimatoprost may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01214</drugbank-id>
      <name>Metipranolol</name>
      <description>Telmisartan may increase the hypotensive activities of Metipranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06826</drugbank-id>
      <name>Unoprostone</name>
      <description>Telmisartan may increase the hypotensive activities of Unoprostone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00484</drugbank-id>
      <name>Brimonidine</name>
      <description>Brimonidine may increase the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09220</drugbank-id>
      <name>Nicorandil</name>
      <description>The risk or severity of hyperkalemia can be increased when Nicorandil is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Icosapent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Mesalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Nabumetone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Tenoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Celecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Tolmetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Rofecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Piroxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Fenoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Valdecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Diclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Sulindac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Flurbiprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Etodolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Mefenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Naproxen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Phenylbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Meloxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Carprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Diflunisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Salicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Meclofenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Oxaprozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Ketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Balsalazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Ibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Olsalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Lumiracoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Magnesium salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Salsalate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Choline magnesium trisalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Antrafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Aminophenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Antipyrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Tiaprofenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Etoricoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02224</drugbank-id>
      <name>Taxifolin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Taxifolin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Oxyphenbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Niflumic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04725</drugbank-id>
      <name>Licofelone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Licofelone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Nimesulide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Benoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Metamizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Zomepirac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Cimicoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Lornoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Aceclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Zaltoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Azapropazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Felbinac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Parecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Salicylamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Kebuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Isoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Indoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Ibuproxam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Floctafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Fenbufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Etofenamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Epirizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Benzydamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Loxoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Dexibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Dexketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Droxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Tolfenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Firocoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Clonixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Morniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Propacetamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Talniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Robenacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Tepoxalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Flunixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12399</drugbank-id>
      <name>Polmacoxib</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Polmacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Nitroaspirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Betulinic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Indobufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Ebselen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Tinoridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Alclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Fentiazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Suxibuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Bumadizone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Alminoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Flunoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Feprazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Difenpiramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Nifenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Lonazolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Tenidap.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Bendazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Pranoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Propyphenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Proglumetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Guacetisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Ethenzamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Carbaspirin calcium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Mofebutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Proquazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Benorilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Pirprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Acemetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Imidazole salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with SC-236.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with NS-398.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14938</drugbank-id>
      <name>Flurbiprofen axetil</name>
      <description>The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Flurbiprofen axetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>Sildenafil may increase the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>Milrinone may increase the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>Anagrelide may increase the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>Theophylline may increase the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00820</drugbank-id>
      <name>Tadalafil</name>
      <description>Tadalafil may increase the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00862</drugbank-id>
      <name>Vardenafil</name>
      <description>Vardenafil may increase the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>Dipyridamole may increase the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>Ibudilast may increase the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06237</drugbank-id>
      <name>Avanafil</name>
      <description>Avanafil may increase the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06267</drugbank-id>
      <name>Udenafil</name>
      <description>Udenafil may increase the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09273</drugbank-id>
      <name>Doxofylline</name>
      <description>Doxofylline may increase the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11792</drugbank-id>
      <name>Mirodenafil</name>
      <description>Mirodenafil may increase the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12010</drugbank-id>
      <name>Fostamatinib</name>
      <description>Fostamatinib may increase the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>Treprostinil may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>Iloprost may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Epoprostenol may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14337</drugbank-id>
      <name>Salvia miltiorrhiza root</name>
      <description>Salvia miltiorrhiza root may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>Amphetamine may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>Linezolid may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>Furazolidone may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>Procaine may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>Tranylcypromine may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>Phenelzine may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>Minaprine may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>Selegiline may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>Procarbazine may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>Moclobemide may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>Isocarboxazid may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>Rasagiline may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>Pargyline may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04017</drugbank-id>
      <name>Clorgiline</name>
      <description>Clorgiline may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>Iproniazid may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>Nialamide may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>Safinamide may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Methylene blue may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>Hydracarbazine may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>Pirlindole may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>Toloxatone may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>Benmoxin may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>Mebanazine may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>Octamoxin may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>Pheniprazine may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>Phenoxypropazine may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>Pivhydrazine may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>Safrazine may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>Caroxazone may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13875</drugbank-id>
      <name>Harmaline</name>
      <description>Harmaline may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13876</drugbank-id>
      <name>Brofaromine</name>
      <description>Brofaromine may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>Butalbital may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>Pentobarbital may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>Secobarbital may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>Methohexital may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>Primidone may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>Methylphenobarbital may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>Thiamylal may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>Amobarbital may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>Hexobarbital may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>Barbital may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09001</drugbank-id>
      <name>Barbexaclone</name>
      <description>Barbexaclone may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Triamterene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00594</drugbank-id>
      <name>Amiloride</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Amiloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09015</drugbank-id>
      <name>Canrenoic acid</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Canrenoic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12221</drugbank-id>
      <name>Canrenone</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Canrenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Esmolol is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>The risk or severity of hyperkalemia can be increased when Fluconazole is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Isradipine is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Atenolol is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Nimodipine is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Nisoldipine is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Ardeparin is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>The risk or severity of hyperkalemia can be increased when Sotalol is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Lercanidipine is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The risk or severity of hyperkalemia can be increased when Cinnarizine is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The risk or severity of hyperkalemia can be increased when Labetalol is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Bisoprolol is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The risk or severity of hyperkalemia can be increased when Magnesium sulfate is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>The risk or severity of hyperkalemia can be increased when Pentamidine is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00825</drugbank-id>
      <name>Levomenthol</name>
      <description>The risk or severity of hyperkalemia can be increased when Levomenthol is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Alprenolol is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Pindolol is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Sulfamethoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Felodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Nitrendipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01074</drugbank-id>
      <name>Perhexiline</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Perhexiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01219</drugbank-id>
      <name>Dantrolene</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Dantrolene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Bevantolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Practolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Penbutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02968</drugbank-id>
      <name>Penicillin G Acyl-Serine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Penicillin G Acyl-Serine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04825</drugbank-id>
      <name>Prenylamine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Prenylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04838</drugbank-id>
      <name>Cyclandelate</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Cyclandelate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Flunarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Fluspirilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Clevidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05885</drugbank-id>
      <name>Seletracetam</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Seletracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06152</drugbank-id>
      <name>Nylidrin</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Nylidrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Ziconotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06446</drugbank-id>
      <name>Dotarizine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Dotarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Nilvadipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Bufuralol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06767</drugbank-id>
      <name>Ammonium chloride</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Ammonium chloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Tinzaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Tranilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Bopindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Bupranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08838</drugbank-id>
      <name>Agmatine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Agmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Indenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08980</drugbank-id>
      <name>Fendiline</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Fendiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08992</drugbank-id>
      <name>Eperisone</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Eperisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09013</drugbank-id>
      <name>Befunolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Befunolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Trimebutine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09090</drugbank-id>
      <name>Pinaverium</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Pinaverium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Arotinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09229</drugbank-id>
      <name>Aranidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Aranidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09230</drugbank-id>
      <name>Azelnidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Azelnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09231</drugbank-id>
      <name>Benidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Benidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09232</drugbank-id>
      <name>Cilnidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Cilnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09234</drugbank-id>
      <name>Darodipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Darodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Efonidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Manidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Niguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09240</drugbank-id>
      <name>Niludipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Niludipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Bemiparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Parnaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09351</drugbank-id>
      <name>Levobetaxolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Levobetaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Anisodamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11960</drugbank-id>
      <name>Carboxyamidotriazole</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Carboxyamidotriazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Naftopidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12097</drugbank-id>
      <name>Mannitol busulfan</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Mannitol busulfan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Vinpocetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Landiolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Bucindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12923</drugbank-id>
      <name>Gallopamil</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Gallopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Esatenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13488</drugbank-id>
      <name>Bencyclane</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Bencyclane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Otilonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Cloranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13530</drugbank-id>
      <name>Mepindolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Mepindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13725</drugbank-id>
      <name>Terodiline</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Terodiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Epanolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13766</drugbank-id>
      <name>Lidoflazine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Lidoflazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13775</drugbank-id>
      <name>Tertatolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Tertatolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Penfluridol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13835</drugbank-id>
      <name>Caroverine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Caroverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13950</drugbank-id>
      <name>WIN 55212-2</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with WIN 55212-2.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13961</drugbank-id>
      <name>Fish oil</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Fish oil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14063</drugbank-id>
      <name>Dexverapamil</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Dexverapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14064</drugbank-id>
      <name>Emopamil</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Emopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14065</drugbank-id>
      <name>Lomerizine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Lomerizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Dexniguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The risk or severity of hyperkalemia can be increased when Nebivolol is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09449</drugbank-id>
      <name>Sodium phosphate, monobasic</name>
      <description>The risk or severity of nephrotoxicity can be increased when Telmisartan is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Valsartan is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00212</drugbank-id>
      <name>Remikiren</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Remikiren is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Olmesartan is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Fosinopril is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00519</drugbank-id>
      <name>Trandolapril</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Trandolapril is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Benazepril is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalapril is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Losartan is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Moexipril is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Lisinopril is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Perindopril is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Candesartan cilexetil is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Eprosartan is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Quinapril is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00886</drugbank-id>
      <name>Omapatrilat</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Omapatrilat is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Telmisartan is combined with Irbesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01342</drugbank-id>
      <name>Forasartan</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Telmisartan is combined with Forasartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01347</drugbank-id>
      <name>Saprisartan</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Telmisartan is combined with Saprisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01349</drugbank-id>
      <name>Tasosartan</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Telmisartan is combined with Tasosartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06763</drugbank-id>
      <name>Saralasin</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Telmisartan is combined with Saralasin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08822</drugbank-id>
      <name>Azilsartan medoxomil</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Telmisartan is combined with Azilsartan medoxomil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09279</drugbank-id>
      <name>Fimasartan</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Telmisartan is combined with Fimasartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Telmisartan is combined with Candesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01180</drugbank-id>
      <name>Rescinnamine</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Rescinnamine is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Captopril is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Cilazapril is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01348</drugbank-id>
      <name>Spirapril</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Spirapril is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03395</drugbank-id>
      <name>Enalkiren</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08836</drugbank-id>
      <name>Temocapril</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Temocapril is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalaprilat is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11783</drugbank-id>
      <name>Imidapril</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Imidapril is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12416</drugbank-id>
      <name>VTP-27999</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13166</drugbank-id>
      <name>Zofenopril</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Zofenopril is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13312</drugbank-id>
      <name>Delapril</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Delapril is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14125</drugbank-id>
      <name>Benazeprilat</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Benazeprilat is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14207</drugbank-id>
      <name>Fosinoprilat</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Fosinoprilat is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14208</drugbank-id>
      <name>Ramiprilat</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Ramiprilat is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14209</drugbank-id>
      <name>Trandolaprilat</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Trandolaprilat is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14210</drugbank-id>
      <name>Moexiprilat</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Moexiprilat is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14213</drugbank-id>
      <name>Perindoprilat</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Perindoprilat is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14217</drugbank-id>
      <name>Quinaprilat</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Quinaprilat is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14231</drugbank-id>
      <name>Quinoline Yellow WS</name>
      <description>The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Quinoline Yellow WS is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>Telmisartan may increase the hypotensive activities of Lacidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>Ethanol may increase the hypotensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09227</drugbank-id>
      <name>Barnidipine</name>
      <description>Telmisartan may increase the antihypertensive activities of Barnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13967</drugbank-id>
      <name>Patent Blue</name>
      <description>The therapeutic efficacy of Telmisartan can be decreased when used in combination with Patent Blue.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>Dexamethasone may increase the excretion rate of Telmisartan which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03619</drugbank-id>
      <name>Deoxycholic acid</name>
      <description>Deoxycholic acid may increase the excretion rate of Telmisartan which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>Taurocholic acid may increase the excretion rate of Telmisartan which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>Fluvoxamine may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>Glimepiride may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>Lovastatin may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00301</drugbank-id>
      <name>Flucloxacillin</name>
      <description>Flucloxacillin may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>Rosiglitazone may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>Atropine may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>Efavirenz may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00637</drugbank-id>
      <name>Astemizole</name>
      <description>Astemizole may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00693</drugbank-id>
      <name>Fluorescein</name>
      <description>Fluorescein may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00822</drugbank-id>
      <name>Disulfiram</name>
      <description>Disulfiram may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00833</drugbank-id>
      <name>Cefaclor</name>
      <description>Cefaclor may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>Mifepristone may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00911</drugbank-id>
      <name>Tinidazole</name>
      <description>Tinidazole may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>Repaglinide may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01039</drugbank-id>
      <name>Fenofibrate</name>
      <description>Telmisartan may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>Telmisartan may decrease the excretion rate of Glipizide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01138</drugbank-id>
      <name>Sulfinpyrazone</name>
      <description>Telmisartan may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>Telmisartan may decrease the excretion rate of Nefazodone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>Telmisartan may decrease the excretion rate of Ofloxacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>Telmisartan may decrease the excretion rate of Lopinavir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05804</drugbank-id>
      <name>Prasterone sulfate</name>
      <description>Telmisartan may decrease the excretion rate of Prasterone sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09374</drugbank-id>
      <name>Indocyanine green acid form</name>
      <description>Telmisartan may decrease the excretion rate of Indocyanine green acid form which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12319</drugbank-id>
      <name>Benzbromarone</name>
      <description>Telmisartan may decrease the excretion rate of Benzbromarone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12712</drugbank-id>
      <name>Pilsicainide</name>
      <description>Telmisartan may decrease the excretion rate of Pilsicainide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13345</drugbank-id>
      <name>Dihydroergocristine</name>
      <description>Telmisartan may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13751</drugbank-id>
      <name>Glycyrrhizic acid</name>
      <description>Telmisartan may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02123</drugbank-id>
      <name>Glycochenodeoxycholic Acid</name>
      <description>Telmisartan may decrease the excretion rate of Glycochenodeoxycholic Acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00761</drugbank-id>
      <name>Potassium chloride</name>
      <description>Potassium chloride may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06715</drugbank-id>
      <name>Potassium Iodide</name>
      <description>Potassium Iodide may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09087</drugbank-id>
      <name>Potassium alum</name>
      <description>Potassium alum may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>Potassium citrate may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09413</drugbank-id>
      <name>Monopotassium phosphate</name>
      <description>Monopotassium phosphate may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09414</drugbank-id>
      <name>Dipotassium phosphate</name>
      <description>Dipotassium phosphate may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09418</drugbank-id>
      <name>Potassium perchlorate</name>
      <description>Potassium perchlorate may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09483</drugbank-id>
      <name>Potassium lactate</name>
      <description>Potassium lactate may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11090</drugbank-id>
      <name>Potassium nitrate</name>
      <description>Potassium nitrate may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11098</drugbank-id>
      <name>Potassium bicarbonate</name>
      <description>Potassium bicarbonate may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11107</drugbank-id>
      <name>Potassium bitartrate</name>
      <description>Potassium bitartrate may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11153</drugbank-id>
      <name>Potassium hydroxide</name>
      <description>Potassium hydroxide may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13620</drugbank-id>
      <name>Potassium gluconate</name>
      <description>Potassium gluconate may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13735</drugbank-id>
      <name>Potassium Guaiacolsulfonate</name>
      <description>Potassium Guaiacolsulfonate may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13831</drugbank-id>
      <name>Potassium permanganate</name>
      <description>Potassium permanganate may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13977</drugbank-id>
      <name>Potassium carbonate</name>
      <description>Potassium carbonate may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14492</drugbank-id>
      <name>Potassium triiodide</name>
      <description>Potassium triiodide may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14498</drugbank-id>
      <name>Potassium acetate</name>
      <description>Potassium acetate may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14499</drugbank-id>
      <name>Potassium sulfate</name>
      <description>Potassium sulfate may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>The risk or severity of angioedema can be increased when Alteplase is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>The risk or severity of angioedema can be increased when Urokinase is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>The risk or severity of angioedema can be increased when Reteplase is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>The risk or severity of angioedema can be increased when Anistreplase is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>The risk or severity of angioedema can be increased when Tenecteplase is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The risk or severity of angioedema can be increased when Streptokinase is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>The risk or severity of angioedema can be increased when Pregabalin is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Vildagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06011</drugbank-id>
      <name>AMG-222</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with AMG-222.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06127</drugbank-id>
      <name>Bisegliptin</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Bisegliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06196</drugbank-id>
      <name>Icatibant</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Icatibant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Alogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06245</drugbank-id>
      <name>Lanoteplase</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Lanoteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Saxagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06679</drugbank-id>
      <name>Amediplase</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Amediplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08382</drugbank-id>
      <name>Gosogliptin</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Gosogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11723</drugbank-id>
      <name>Dutogliptin</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Dutogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11950</drugbank-id>
      <name>Teneligliptin</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Teneligliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11992</drugbank-id>
      <name>Omarigliptin</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Omarigliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12268</drugbank-id>
      <name>Carmegliptin</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Carmegliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12412</drugbank-id>
      <name>Gemigliptin</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Gemigliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12417</drugbank-id>
      <name>Anagliptin</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Anagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12625</drugbank-id>
      <name>Evogliptin</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Evogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13646</drugbank-id>
      <name>Saruplase</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Saruplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09292</drugbank-id>
      <name>Sacubitril</name>
      <description>The risk or severity of angioedema can be increased when Telmisartan is combined with Sacubitril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>The metabolism of Telmisartan can be decreased when combined with Vilazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The metabolism of Methadone can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The metabolism of Trimethadione can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00395</drugbank-id>
      <name>Carisoprodol</name>
      <description>The metabolism of Carisoprodol can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>The metabolism of Zolpidem can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The metabolism of Fluoxetine can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00518</drugbank-id>
      <name>Albendazole</name>
      <description>The metabolism of Albendazole can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The metabolism of Cyclophosphamide can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00582</drugbank-id>
      <name>Voriconazole</name>
      <description>The metabolism of Voriconazole can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The metabolism of Doxazosin can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The metabolism of Thioridazine can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00736</drugbank-id>
      <name>Esomeprazole</name>
      <description>The metabolism of Esomeprazole can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The metabolism of Zonisamide can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>The metabolism of Ramelteon can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01058</drugbank-id>
      <name>Praziquantel</name>
      <description>The metabolism of Praziquantel can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>The metabolism of Rabeprazole can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01131</drugbank-id>
      <name>Proguanil</name>
      <description>The metabolism of Proguanil can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The metabolism of Escitalopram can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>The metabolism of Lapatinib can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The metabolism of St. John's Wort can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The metabolism of Methsuximide can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05351</drugbank-id>
      <name>Dexlansoprazole</name>
      <description>The metabolism of Dexlansoprazole can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>The metabolism of Lacosamide can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06414</drugbank-id>
      <name>Etravirine</name>
      <description>The metabolism of Etravirine can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06697</drugbank-id>
      <name>Artemether</name>
      <description>The metabolism of Artemether can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06739</drugbank-id>
      <name>Seratrodast</name>
      <description>The metabolism of Seratrodast can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The metabolism of (R)-warfarin can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>The metabolism of Vortioxetine can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09166</drugbank-id>
      <name>Etizolam</name>
      <description>The metabolism of Etizolam can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11823</drugbank-id>
      <name>Esketamine</name>
      <description>The metabolism of Esketamine can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12130</drugbank-id>
      <name>Lorlatinib</name>
      <description>The metabolism of Lorlatinib can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12245</drugbank-id>
      <name>Triclabendazole</name>
      <description>The metabolism of Triclabendazole can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>The metabolism of Lynestrenol can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13762</drugbank-id>
      <name>Dexrabeprazole</name>
      <description>The metabolism of Dexrabeprazole can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The metabolism of (S)-Warfarin can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The metabolism of Paroxetine can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14975</drugbank-id>
      <name>Voxelotor</name>
      <description>The metabolism of Voxelotor can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>The metabolism of Cenobamate can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The metabolism of Verapamil can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The metabolism of Sertraline can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The metabolism of Thiopental can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The metabolism of Warfarin can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The metabolism of Amiodarone can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The metabolism of Doxepin can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The metabolism of Clomipramine can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The metabolism of Fosphenytoin can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The metabolism of Acenocoumarol can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The excretion of Methotrexate can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>The risk or severity of adverse effects can be increased when Baclofen is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>The metabolism of Telmisartan can be decreased when combined with Gemfibrozil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>The metabolism of Telmisartan can be decreased when combined with Flunitrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The metabolism of Telmisartan can be decreased when combined with Deferasirox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05928</drugbank-id>
      <name>Dovitinib</name>
      <description>The metabolism of Telmisartan can be decreased when combined with Dovitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>The metabolism of Telmisartan can be decreased when combined with Eltrombopag.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00190</drugbank-id>
      <name>Carbidopa</name>
      <description>The risk or severity of hypotension can be increased when Carbidopa is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>Telmisartan may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The therapeutic efficacy of Telmisartan can be decreased when used in combination with Ketorolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The risk or severity of hypotension can be increased when Prazosin is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Bortezomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Torasemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Ropinirole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Ropivacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00297</drugbank-id>
      <name>Bupivacaine</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Bupivacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Chlorthalidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Tolcapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Nitroprusside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00350</drugbank-id>
      <name>Minoxidil</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Minoxidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00413</drugbank-id>
      <name>Pramipexole</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00435</drugbank-id>
      <name>Nitric Oxide</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Nitric Oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00486</drugbank-id>
      <name>Nabilone</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Nabilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Metolazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Dexmedetomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Mecamylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00681</drugbank-id>
      <name>Amphotericin B</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Amphotericin B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00692</drugbank-id>
      <name>Phentolamine</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Phentolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Furosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Tizanidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Methazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Tamsulosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Sufentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00714</drugbank-id>
      <name>Apomorphine</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Apomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00727</drugbank-id>
      <name>Nitroglycerin</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Nitroglycerin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Isoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Tretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00797</drugbank-id>
      <name>Tolazoline</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Tolazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00800</drugbank-id>
      <name>Fenoldopam</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Fenoldopam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Indapamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Propofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Conivaptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00883</drugbank-id>
      <name>Isosorbide dinitrate</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Isosorbide dinitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Bumetanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Remifentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Etacrynic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00922</drugbank-id>
      <name>Levosimendan</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Levosimendan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00925</drugbank-id>
      <name>Phenoxybenzamine</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Phenoxybenzamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00217</drugbank-id>
      <name>Bethanidine</name>
      <description>The therapeutic efficacy of Bethanidine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00226</drugbank-id>
      <name>Guanadrel</name>
      <description>The therapeutic efficacy of Guanadrel can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00616</drugbank-id>
      <name>Candoxatril</name>
      <description>The therapeutic efficacy of Candoxatril can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00629</drugbank-id>
      <name>Guanabenz</name>
      <description>The therapeutic efficacy of Guanabenz can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00765</drugbank-id>
      <name>Metyrosine</name>
      <description>The therapeutic efficacy of Metyrosine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00785</drugbank-id>
      <name>Cryptenamine</name>
      <description>The therapeutic efficacy of Cryptenamine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>The therapeutic efficacy of Methyldopa can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>The therapeutic efficacy of Guanfacine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01089</drugbank-id>
      <name>Deserpidine</name>
      <description>The therapeutic efficacy of Deserpidine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The therapeutic efficacy of Pentolinium can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The therapeutic efficacy of Trimethaphan can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01158</drugbank-id>
      <name>Bretylium</name>
      <description>The therapeutic efficacy of Bretylium can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01162</drugbank-id>
      <name>Terazosin</name>
      <description>The therapeutic efficacy of Terazosin can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01170</drugbank-id>
      <name>Guanethidine</name>
      <description>The therapeutic efficacy of Guanethidine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01275</drugbank-id>
      <name>Hydralazine</name>
      <description>The therapeutic efficacy of Hydralazine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03322</drugbank-id>
      <name>Dexpropranolol</name>
      <description>The therapeutic efficacy of Dexpropranolol can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04831</drugbank-id>
      <name>Tienilic acid</name>
      <description>The therapeutic efficacy of Tienilic acid can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>The therapeutic efficacy of Lofexidine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06268</drugbank-id>
      <name>Sitaxentan</name>
      <description>The therapeutic efficacy of Sitaxentan can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06445</drugbank-id>
      <name>Diethylnorspermine</name>
      <description>The therapeutic efficacy of Diethylnorspermine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06762</drugbank-id>
      <name>Pinacidil</name>
      <description>The therapeutic efficacy of Pinacidil can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>The therapeutic efficacy of Ferulic acid can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08932</drugbank-id>
      <name>Macitentan</name>
      <description>The therapeutic efficacy of Macitentan can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08950</drugbank-id>
      <name>Indoramin</name>
      <description>The therapeutic efficacy of Indoramin can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The therapeutic efficacy of Hexamethonium can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09206</drugbank-id>
      <name>Trimazosin</name>
      <description>The therapeutic efficacy of Trimazosin can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09242</drugbank-id>
      <name>Moxonidine</name>
      <description>The therapeutic efficacy of Moxonidine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09363</drugbank-id>
      <name>Rauwolfia serpentina root</name>
      <description>The therapeutic efficacy of Rauwolfia serpentina root can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11720</drugbank-id>
      <name>Angiotensin 1-7</name>
      <description>The therapeutic efficacy of Angiotensin 1-7 can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11738</drugbank-id>
      <name>Rilmenidine</name>
      <description>The therapeutic efficacy of Rilmenidine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12054</drugbank-id>
      <name>BQ-123</name>
      <description>The therapeutic efficacy of BQ-123 can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>The therapeutic efficacy of Ketanserin can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12661</drugbank-id>
      <name>Urapidil</name>
      <description>The therapeutic efficacy of Urapidil can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12766</drugbank-id>
      <name>Cicletanine</name>
      <description>The therapeutic efficacy of Cicletanine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12945</drugbank-id>
      <name>Dihydralazine</name>
      <description>The therapeutic efficacy of Dihydralazine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13211</drugbank-id>
      <name>Guanoxan</name>
      <description>The therapeutic efficacy of Guanoxan can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13374</drugbank-id>
      <name>Vincamine</name>
      <description>The therapeutic efficacy of Vincamine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>The therapeutic efficacy of Linsidomine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13410</drugbank-id>
      <name>Guanoxabenz</name>
      <description>The therapeutic efficacy of Guanoxabenz can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13429</drugbank-id>
      <name>Tolonidine</name>
      <description>The therapeutic efficacy of Tolonidine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13435</drugbank-id>
      <name>Endralazine</name>
      <description>The therapeutic efficacy of Endralazine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13452</drugbank-id>
      <name>Cadralazine</name>
      <description>The therapeutic efficacy of Cadralazine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13575</drugbank-id>
      <name>Bietaserpine</name>
      <description>The therapeutic efficacy of Bietaserpine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13604</drugbank-id>
      <name>Guanazodine</name>
      <description>The therapeutic efficacy of Guanazodine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13631</drugbank-id>
      <name>Methoserpidine</name>
      <description>The therapeutic efficacy of Methoserpidine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13779</drugbank-id>
      <name>Guanoclor</name>
      <description>The therapeutic efficacy of Guanoclor can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13801</drugbank-id>
      <name>Muzolimine</name>
      <description>The therapeutic efficacy of Muzolimine can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>The therapeutic efficacy of Xipamide can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>The therapeutic efficacy of Tocopherylquinone can be increased when used in combination with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Levobupivacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01020</drugbank-id>
      <name>Isosorbide mononitrate</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Isosorbide mononitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01113</drugbank-id>
      <name>Papaverine</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Diclofenamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Halothane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Desflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Sevoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01282</drugbank-id>
      <name>Carbetocin</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Carbetocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01612</drugbank-id>
      <name>Amyl Nitrite</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Amyl Nitrite.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04899</drugbank-id>
      <name>Nesiritide</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Nesiritide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05271</drugbank-id>
      <name>Rotigotine</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Rotigotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08941</drugbank-id>
      <name>Isoxsuprine</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Isoxsuprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Empagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09112</drugbank-id>
      <name>Nitrous acid</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Nitrous acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Pipamperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The serum concentration of Digoxin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>The serum concentration of Metildigoxin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>The serum concentration of Acetyldigoxin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The risk or severity of hypotension can be increased when Clonidine is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>Telmisartan may increase the hypotensive activities of Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14500</drugbank-id>
      <name>Potassium</name>
      <description>Potassium may increase the hyperkalemic activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>The serum concentration of Afatinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The serum concentration of Bosutinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The serum concentration of Brentuximab vedotin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The serum concentration of Colchicine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The serum concentration of Edoxaban can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09027</drugbank-id>
      <name>Ledipasvir</name>
      <description>The serum concentration of Ledipasvir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09049</drugbank-id>
      <name>Naloxegol</name>
      <description>The serum concentration of Naloxegol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The serum concentration of Pazopanib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>The serum concentration of Prucalopride can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>The serum concentration of Ranolazine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06207</drugbank-id>
      <name>Silodosin</name>
      <description>The serum concentration of Silodosin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The serum concentration of Topotecan can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The serum concentration of Everolimus can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01220</drugbank-id>
      <name>Rifaximin</name>
      <description>The serum concentration of Rifaximin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The excretion of Vincristine can be decreased when combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The serum concentration of Doxorubicin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>The serum concentration of Betrixaban can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The serum concentration of Phenytoin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The serum concentration of Amitriptyline can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The serum concentration of Imipramine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The serum concentration of Carbamazepine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The serum concentration of Trimipramine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The serum concentration of Tacrolimus can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The serum concentration of Sirolimus can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The serum concentration of Quinidine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The serum concentration of Rifampicin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The serum concentration of Phenobarbital can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The serum concentration of Paclitaxel can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The serum concentration of Temsirolimus can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12015</drugbank-id>
      <name>Alpelisib</name>
      <description>The serum concentration of Alpelisib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12825</drugbank-id>
      <name>Lefamulin</name>
      <description>Telmisartan may decrease the excretion rate of Lefamulin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00027</drugbank-id>
      <name>Gramicidin D</name>
      <description>The serum concentration of Gramicidin D can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>The serum concentration of Octreotide can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00126</drugbank-id>
      <name>Ascorbic acid</name>
      <description>The serum concentration of Ascorbic acid can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>The serum concentration of Pravastatin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The serum concentration of Tramadol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The serum concentration of Erythromycin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00207</drugbank-id>
      <name>Azithromycin</name>
      <description>The serum concentration of Azithromycin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>The serum concentration of Pantoprazole can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The serum concentration of Eletriptan can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The serum concentration of Nelfinavir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The serum concentration of Indinavir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The serum concentration of Cabergoline can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The serum concentration of Diethylstilbestrol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The serum concentration of Metoprolol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>The serum concentration of Topiramate can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The serum concentration of Venlafaxine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The serum concentration of Conjugated estrogens can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00291</drugbank-id>
      <name>Chlorambucil</name>
      <description>The serum concentration of Chlorambucil can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The serum concentration of Morphine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir disoproxil</name>
      <description>The serum concentration of Tenofovir disoproxil can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00305</drugbank-id>
      <name>Mitomycin</name>
      <description>The serum concentration of Mitomycin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The serum concentration of Acetaminophen can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>The serum concentration of Gefitinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The serum concentration of Olanzapine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The serum concentration of Omeprazole can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>The serum concentration of Cetirizine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The serum concentration of Terfenadine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The serum concentration of Diltiazem can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The serum concentration of Clobazam can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>The serum concentration of Mefloquine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The serum concentration of Vinorelbine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The serum concentration of Clozapine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The serum concentration of Grepafloxacin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The serum concentration of Timolol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The serum concentration of Tacrine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The serum concentration of Beclomethasone dipropionate can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The serum concentration of Sorafenib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The serum concentration of Cerivastatin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>The serum concentration of Gemcitabine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The serum concentration of Betamethasone can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>The serum concentration of Teniposide can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>The serum concentration of Lansoprazole can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The serum concentration of Quinine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>The serum concentration of Lenalidomide can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The serum concentration of Zidovudine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The serum concentration of Haloperidol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The serum concentration of Ritonavir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The serum concentration of Cisplatin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00523</drugbank-id>
      <name>Alitretinoin</name>
      <description>The serum concentration of Alitretinoin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The serum concentration of Erlotinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>The serum concentration of Toremifene can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The serum concentration of Lamotrigine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>The serum concentration of Nizatidine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The serum concentration of Fluticasone propionate can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00602</drugbank-id>
      <name>Ivermectin</name>
      <description>The serum concentration of Ivermectin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The serum concentration of Chloroquine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The serum concentration of Imatinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The serum concentration of Nicardipine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The serum concentration of Prednisone can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The serum concentration of Simvastatin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The serum concentration of Pentazocine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>The serum concentration of Sumatriptan can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The serum concentration of Mycophenolate mofetil can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The serum concentration of Daunorubicin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00701</drugbank-id>
      <name>Amprenavir</name>
      <description>The serum concentration of Amprenavir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>The serum concentration of Lamivudine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The serum concentration of Hydrocortisone can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>The serum concentration of Mannitol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The serum concentration of Clopidogrel can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The serum concentration of Tetracycline can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The serum concentration of Irinotecan can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>The serum concentration of Olopatadine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The serum concentration of Etoposide can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The serum concentration of Estradiol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The serum concentration of Diazepam can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The serum concentration of Trifluoperazine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The serum concentration of Loperamide can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The serum concentration of Prednisolone can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The serum concentration of Ranitidine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The serum concentration of Flupentixol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00882</drugbank-id>
      <name>Clomifene</name>
      <description>The serum concentration of Clomifene can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The serum concentration of Ondansetron can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>The serum concentration of Fexofenadine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The serum concentration of Methylprednisolone can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The serum concentration of Dactinomycin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00973</drugbank-id>
      <name>Ezetimibe</name>
      <description>The serum concentration of Ezetimibe can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00987</drugbank-id>
      <name>Cytarabine</name>
      <description>The serum concentration of Cytarabine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The serum concentration of Hydroxyurea can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01042</drugbank-id>
      <name>Melphalan</name>
      <description>The serum concentration of Melphalan can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The serum concentration of Atazanavir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The serum concentration of Atorvastatin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The serum concentration of Nifedipine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The serum concentration of Levofloxacin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>The serum concentration of Itraconazole can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The serum concentration of Arsenic trioxide can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01183</drugbank-id>
      <name>Naloxone</name>
      <description>The serum concentration of Naloxone can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The serum concentration of Domperidone can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The serum concentration of Acebutolol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The serum concentration of Bromocriptine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The serum concentration of Levetiracetam can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The serum concentration of Nadolol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The serum concentration of Mitoxantrone can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>The serum concentration of Sparfloxacin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The serum concentration of Clarithromycin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The serum concentration of Saquinavir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The serum concentration of Docetaxel can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The serum concentration of Dasatinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The serum concentration of Sitagliptin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01263</drugbank-id>
      <name>Posaconazole</name>
      <description>The serum concentration of Posaconazole can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The serum concentration of Paliperidone can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The serum concentration of Sunitinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The serum concentration of Vecuronium can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01400</drugbank-id>
      <name>Neostigmine</name>
      <description>The serum concentration of Neostigmine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01420</drugbank-id>
      <name>Testosterone propionate</name>
      <description>The serum concentration of Testosterone propionate can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>The serum concentration of Ketazolam can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02901</drugbank-id>
      <name>Stanolone</name>
      <description>The serum concentration of Stanolone can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03203</drugbank-id>
      <name>Sphingosine</name>
      <description>The serum concentration of Sphingosine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03825</drugbank-id>
      <name>Rhodamine 6G</name>
      <description>The serum concentration of Rhodamine 6G can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>The serum concentration of Estriol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The serum concentration of Aldosterone can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04690</drugbank-id>
      <name>Camptothecin</name>
      <description>The serum concentration of Camptothecin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquine</name>
      <description>The serum concentration of Debrisoquine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The serum concentration of Celiprolol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The serum concentration of Nilotinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The serum concentration of Belinostat can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The serum concentration of Indacaterol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05239</drugbank-id>
      <name>Cobimetinib</name>
      <description>The serum concentration of Cobimetinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05521</drugbank-id>
      <name>Telaprevir</name>
      <description>The serum concentration of Telaprevir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The serum concentration of Trastuzumab emtansine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05889</drugbank-id>
      <name>Inotuzumab ozogamicin</name>
      <description>The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06176</drugbank-id>
      <name>Romidepsin</name>
      <description>The serum concentration of Romidepsin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The serum concentration of Rivaroxaban can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The serum concentration of Dapagliflozin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>The serum concentration of Ambrisentan can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The serum concentration of Panobinostat can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The serum concentration of Apixaban can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The serum concentration of Axitinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06670</drugbank-id>
      <name>Odanacatib</name>
      <description>The serum concentration of Odanacatib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The serum concentration of Fesoterodine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The serum concentration of Cabazitaxel can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The serum concentration of Ticagrelor can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08828</drugbank-id>
      <name>Vismodegib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>The serum concentration of Pitavastatin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The serum concentration of Crizotinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08874</drugbank-id>
      <name>Fidaxomicin</name>
      <description>The serum concentration of Fidaxomicin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The serum concentration of Vemurafenib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The serum concentration of Linagliptin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The serum concentration of Carfilzomib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The serum concentration of Mirabegron can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>The serum concentration of Regorafenib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The serum concentration of Ponatinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The serum concentration of Fluticasone furoate can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The serum concentration of Pomalidomide can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The serum concentration of Dabrafenib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The serum concentration of Levomilnacipran can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08930</drugbank-id>
      <name>Dolutegravir</name>
      <description>The serum concentration of Dolutegravir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08934</drugbank-id>
      <name>Sofosbuvir</name>
      <description>The serum concentration of Sofosbuvir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The serum concentration of Idelalisib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The serum concentration of Ceritinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The serum concentration of Olaparib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The serum concentration of Umeclidinium can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The serum concentration of Nintedanib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09099</drugbank-id>
      <name>Somatostatin</name>
      <description>The serum concentration of Somatostatin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09161</drugbank-id>
      <name>Technetium Tc-99m sestamibi</name>
      <description>The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09183</drugbank-id>
      <name>Dasabuvir</name>
      <description>The serum concentration of Dasabuvir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09270</drugbank-id>
      <name>Ubidecarenone</name>
      <description>The serum concentration of Ubidecarenone can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09296</drugbank-id>
      <name>Ombitasvir</name>
      <description>The serum concentration of Ombitasvir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09297</drugbank-id>
      <name>Paritaprevir</name>
      <description>The serum concentration of Paritaprevir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09299</drugbank-id>
      <name>Tenofovir alafenamide</name>
      <description>The serum concentration of Tenofovir alafenamide can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The serum concentration of Osimertinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>The serum concentration of Selexipag can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11431</drugbank-id>
      <name>Moxidectin</name>
      <description>The serum concentration of Moxidectin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11447</drugbank-id>
      <name>Phenothiazine</name>
      <description>The serum concentration of Phenothiazine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11574</drugbank-id>
      <name>Elbasvir</name>
      <description>The serum concentration of Elbasvir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11575</drugbank-id>
      <name>Grazoprevir</name>
      <description>The serum concentration of Grazoprevir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>The serum concentration of Venetoclax can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11586</drugbank-id>
      <name>Asunaprevir</name>
      <description>The serum concentration of Asunaprevir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11613</drugbank-id>
      <name>Velpatasvir</name>
      <description>The serum concentration of Velpatasvir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11641</drugbank-id>
      <name>Vinflunine</name>
      <description>The serum concentration of Vinflunine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The serum concentration of Curcumin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11712</drugbank-id>
      <name>Tezacaftor</name>
      <description>The serum concentration of Tezacaftor can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11753</drugbank-id>
      <name>Rifamycin</name>
      <description>The serum concentration of Rifamycin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11760</drugbank-id>
      <name>Talazoparib</name>
      <description>The serum concentration of Talazoparib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The serum concentration of Talinolol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The serum concentration of Baricitinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>The serum concentration of Ertugliflozin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11869</drugbank-id>
      <name>Valspodar</name>
      <description>The serum concentration of Valspodar can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11952</drugbank-id>
      <name>Duvelisib</name>
      <description>The serum concentration of Duvelisib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11979</drugbank-id>
      <name>Elagolix</name>
      <description>The serum concentration of Elagolix can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11995</drugbank-id>
      <name>Avatrombopag</name>
      <description>The serum concentration of Avatrombopag can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12001</drugbank-id>
      <name>Abemaciclib</name>
      <description>The serum concentration of Abemaciclib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12026</drugbank-id>
      <name>Voxilaprevir</name>
      <description>The serum concentration of Voxilaprevir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>The serum concentration of Gilteritinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The serum concentration of Erdafitinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The serum concentration of Rucaparib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>The serum concentration of Bromperidol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12455</drugbank-id>
      <name>Omadacycline</name>
      <description>The serum concentration of Omadacycline can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12483</drugbank-id>
      <name>Copanlisib</name>
      <description>The serum concentration of Copanlisib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12836</drugbank-id>
      <name>Grapiprant</name>
      <description>The serum concentration of Grapiprant can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13125</drugbank-id>
      <name>Lusutrombopag</name>
      <description>The serum concentration of Lusutrombopag can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13146</drugbank-id>
      <name>Fluciclovine (18F)</name>
      <description>The serum concentration of Fluciclovine (18F) can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13173</drugbank-id>
      <name>Cerliponase alfa</name>
      <description>The serum concentration of Cerliponase alfa can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The serum concentration of Fluticasone can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13878</drugbank-id>
      <name>Pibrentasvir</name>
      <description>The serum concentration of Pibrentasvir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13879</drugbank-id>
      <name>Glecaprevir</name>
      <description>The serum concentration of Glecaprevir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13951</drugbank-id>
      <name>Stanolone acetate</name>
      <description>The serum concentration of Stanolone acetate can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>The serum concentration of Estradiol acetate can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>The serum concentration of Estradiol benzoate can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The serum concentration of Estradiol cypionate can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>The serum concentration of Estradiol dienanthate can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The serum concentration of Estradiol valerate can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14126</drugbank-id>
      <name>Tenofovir</name>
      <description>The serum concentration of Tenofovir can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14568</drugbank-id>
      <name>Ivosidenib</name>
      <description>The serum concentration of Ivosidenib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00455</drugbank-id>
      <name>Loratadine</name>
      <description>The serum concentration of Telmisartan can be increased when it is combined with Loratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The serum concentration of Budesonide can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>The serum concentration of Donepezil can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11986</drugbank-id>
      <name>Entrectinib</name>
      <description>The serum concentration of Entrectinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12500</drugbank-id>
      <name>Fedratinib</name>
      <description>The serum concentration of Fedratinib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The serum concentration of Metoclopramide can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>The serum concentration of Oxcarbazepine can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The serum concentration of Flecainide can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01217</drugbank-id>
      <name>Anastrozole</name>
      <description>The serum concentration of Anastrozole can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11732</drugbank-id>
      <name>Lasmiditan</name>
      <description>The serum concentration of Lasmiditan can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13007</drugbank-id>
      <name>Enfortumab vedotin</name>
      <description>The serum concentration of Enfortumab vedotin can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14962</drugbank-id>
      <name>Trastuzumab deruxtecan</name>
      <description>The serum concentration of Trastuzumab deruxtecan can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The serum concentration of Propranolol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15328</drugbank-id>
      <name>Ubrogepant</name>
      <description>The serum concentration of Ubrogepant can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The serum concentration of Cilostazol can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00158</drugbank-id>
      <name>Folic acid</name>
      <description>Telmisartan may decrease the excretion rate of Folic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00242</drugbank-id>
      <name>Cladribine</name>
      <description>Telmisartan may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00437</drugbank-id>
      <name>Allopurinol</name>
      <description>Telmisartan may decrease the excretion rate of Allopurinol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00481</drugbank-id>
      <name>Raloxifene</name>
      <description>Telmisartan may decrease the excretion rate of Raloxifene which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>Telmisartan may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>Telmisartan may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>Telmisartan may decrease the excretion rate of Testosterone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>Telmisartan may decrease the excretion rate of Clofarabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>Telmisartan may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>Telmisartan may decrease the excretion rate of Riluzole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>Telmisartan may decrease the excretion rate of Tegaserod which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>Telmisartan may decrease the excretion rate of Leflunomide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>Telmisartan may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03496</drugbank-id>
      <name>Alvocidib</name>
      <description>Telmisartan may decrease the excretion rate of Alvocidib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>Telmisartan may decrease the excretion rate of Teriflunomide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>Telmisartan may decrease the excretion rate of Riociguat which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>Telmisartan may decrease the excretion rate of Palbociclib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>Telmisartan may decrease the excretion rate of Revefenacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>Telmisartan may decrease the excretion rate of Delafloxacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>Telmisartan may decrease the excretion rate of Dacomitinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11978</drugbank-id>
      <name>Glasdegib</name>
      <description>Telmisartan may decrease the excretion rate of Glasdegib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12267</drugbank-id>
      <name>Brigatinib</name>
      <description>Telmisartan may decrease the excretion rate of Brigatinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>Telmisartan may decrease the excretion rate of Enasidenib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>Telmisartan may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>Telmisartan may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>Telmisartan may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14723</drugbank-id>
      <name>Larotrectinib</name>
      <description>Telmisartan may decrease the excretion rate of Larotrectinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12941</drugbank-id>
      <name>Darolutamide</name>
      <description>Telmisartan may decrease the excretion rate of Darolutamide which could result in a higher serum level.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>6.66</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-5.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>3.50e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>6.04</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>2-(4-{[4-methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]methyl}phenyl)benzoic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>telmisartan</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>514.6169</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>514.236876224</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C33H30N4O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>RMMXLENWKUUMAY-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>72.94</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>164.49</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>58.61</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>3.65</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>6.13</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Practically insoluble</value>
      <source/>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>261-263 C</value>
      <source/>
    </property>
    <property>
      <kind>logP</kind>
      <value>7.7</value>
      <source/>
    </property>
    <property>
      <kind>caco2 Permeability</kind>
      <value>-4.82</value>
      <source>ADME Research, USCD</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11907</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>9434</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>65999</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505370</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07710</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00627</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>59391</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50043280</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA451605</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>TLS</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000766</identifier>
    </external-identifier>
    <external-identifier>
      <resource>IUPHAR</resource>
      <identifier>592</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Guide to Pharmacology</resource>
      <identifier>592</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Telmisartan</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1017</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/telmisartan.htm</url>
    </external-link>
    <external-link>
      <resource>PDRhealth</resource>
      <url>http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/mic1592.shtml</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/telmisartan.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000164</smpdb-id>
      <name>Telmisartan Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00966</drugbank-id>
          <name>Telmisartan</name>
        </drug>
        <drug>
          <drugbank-id>DB01593</drugbank-id>
          <name>Zinc</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P30556</uniprot-id>
        <uniprot-id>P00797</uniprot-id>
        <uniprot-id>P01019</uniprot-id>
        <uniprot-id>P12821</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000062</id>
      <name>Type-1 angiotensin II receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <ref-id>A6000</ref-id>
            <pubmed-id>10067800</pubmed-id>
            <citation>Karlberg BE, Lins LE, Hermansson K: Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens. 1999 Feb;17(2):293-302.</citation>
          </article>
          <article>
            <ref-id>A6001</ref-id>
            <pubmed-id>11444497</pubmed-id>
            <citation>Balt JC, Mathy MJ, Nap A, Pfaffendorf M, van Zwieten PA: Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery. J Cardiovasc Pharmacol. 2001 Jul;38(1):141-8.</citation>
          </article>
          <article>
            <ref-id>A6002</ref-id>
            <pubmed-id>11408526</pubmed-id>
            <citation>Gohlke P, Weiss S, Jansen A, Wienen W, Stangier J, Rascher W, Culman J, Unger T: AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther. 2001 Jul;298(1):62-70.</citation>
          </article>
          <article>
            <ref-id>A6003</ref-id>
            <pubmed-id>9259062</pubmed-id>
            <citation>Strohmenger HU, Lindner KH, Wienen W, Vogt J: Effects of the AT1-selective angiotensin II antagonist, telmisartan, on hemodynamics and ventricular function after cardiopulmonary resuscitation in pigs. Resuscitation. 1997 Aug;35(1):61-8.</citation>
          </article>
          <article>
            <ref-id>A6004</ref-id>
            <pubmed-id>15498586</pubmed-id>
            <citation>Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, Fujikura J, Chusho H, Ebihara K, Hayashi T, Hosoda K, Nakao K: An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 2004 Oct 22;576(3):492-7.</citation>
          </article>
          <article>
            <ref-id>A1489</ref-id>
            <pubmed-id>11558835</pubmed-id>
            <citation>Sharpe M, Jarvis B, Goa KL: Telmisartan: a review of its use in hypertension. Drugs. 2001;61(10):1501-29.</citation>
          </article>
          <article>
            <ref-id>A6005</ref-id>
            <pubmed-id>9878991</pubmed-id>
            <citation>McClellan KJ, Markham A: Telmisartan. Drugs. 1998 Dec;56(6):1039-44; discussion 1045-6.</citation>
          </article>
          <article>
            <ref-id>A1492</ref-id>
            <pubmed-id>20448797</pubmed-id>
            <citation>Galzerano D, Capogrosso C, Di Michele S, Galzerano A, Paparello P, Lama D, Gaudio C: New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag. 2010 Mar 24;6:113-33.</citation>
          </article>
          <article>
            <ref-id>A6006</ref-id>
            <pubmed-id>19147680</pubmed-id>
            <citation>Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, Naruse M: A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology. 2009 Feb;150(2):862-70. doi: 10.1210/en.2008-0502. Epub 2009 Jan 15.</citation>
          </article>
          <article>
            <ref-id>A6007</ref-id>
            <pubmed-id>16938288</pubmed-id>
            <citation>Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K: Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res. 2006 Oct 1;72(1):184-90. Epub 2006 Jul 21.</citation>
          </article>
          <article>
            <ref-id>A6008</ref-id>
            <pubmed-id>18580862</pubmed-id>
            <citation>Kurtz TW: Beyond the classic angiotensin-receptor-blocker profile. Nat Clin Pract Cardiovasc Med. 2008 Jul;5 Suppl 1:S19-26. doi: 10.1038/ncpcardio0805.</citation>
          </article>
          <article>
            <ref-id>A6009</ref-id>
            <pubmed-id>15617852</pubmed-id>
            <citation>Yamagishi S, Takeuchi M: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses. 2005;64(3):476-8.</citation>
          </article>
          <article>
            <ref-id>A6010</ref-id>
            <pubmed-id>17691961</pubmed-id>
            <citation>Yamagishi S, Nakamura K, Matsui T: Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med. 2007 Aug;7(5):463-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P30556" source="Swiss-Prot">
        <name>Type-1 angiotensin II receptor</name>
        <general-function>Protein heterodimerization activity</general-function>
        <specific-function>Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.</specific-function>
        <gene-name>AGTR1</gene-name>
        <locus>3q21-q25</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>28-52
65-87
103-124
143-162
193-214
241-262
276-296</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.71</theoretical-pi>
        <molecular-weight>41060.53</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:336</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>AGTR1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M91464</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>179122</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>34</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>34</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P30556</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>AGTR1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>AGTR1A</synonym>
          <synonym>AGTR1B</synonym>
          <synonym>Angiotensin II type-1 receptor</synonym>
          <synonym>AT1</synonym>
          <synonym>AT1AR</synonym>
          <synonym>AT1BR</synonym>
          <synonym>AT2R1</synonym>
          <synonym>AT2R1B</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009910|Type-1 angiotensin II receptor
MILNSSTEDGIKRIQDDCPKAGRHNYIFVMIPTLYSIIFVVGIFGNSLVVIVIYFYMKLK
TVASVFLLNLALADLCFLLTLPLWAVYTAMEYRWPFGNYLCKIASASVSFNLYASVFLLT
CLSIDRYLAIVHPMKSRLRRTMLVAKVTCIIIWLLAGLASLPAIIHRNVFFIENTNITVC
AFHYESQNSTLPIGLGLTKNILGFLFPFLIILTSYTLIWKALKKAYEIQKNKPRNDDIFK
IIMAIVLFFFFSWIPHQIFTFLDVLIQLGIIRDCRIADIVDTAMPITICIAYFNNCLNPL
FYGFLGKKFKRYFLQLLKYIPPKAKSHSNLSTKMSTLSYRPSDNVSSSTKKPAPCFEVE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009911|Type-1 angiotensin II receptor (AGTR1)
ATGATTCTCAACTCTTCTACTGAAGATGGTATTAAAAGAATCCAAGATGATTGTCCCAAA
GCTGGAAGGCATAATTACATATTTGTCATGATTCCTACTTTATACAGTATCATCTTTGTG
GTGGGAATATTTGGAAACAGCTTGGTGGTGATAGTCATTTACTTTTATATGAAGCTGAAG
ACTGTGGCCAGTGTTTTTCTTTTGAATTTAGCACTGGCTGACTTATGCTTTTTACTGACT
TTGCCACTATGGGCTGTCTACACAGCTATGGAATACCGCTGGCCCTTTGGCAATTACCTA
TGTAAGATTGCTTCAGCCAGCGTCAGTTTCAACCTGTACGCTAGTGTGTTTCTACTCACG
TGTCTCAGCATTGATCGATACCTGGCTATTGTTCACCCAATGAAGTCCCGCCTTCGACGC
ACAATGCTTGTAGCCAAAGTCACCTGCATCATCATTTGGCTGCTGGCAGGCTTGGCCAGT
TTGCCAGCTATAATCCATCGAAATGTATTTTTCATTGAGAACACCAATATTACAGTTTGT
GCTTTCCATTATGAGTCCCAAAATTCAACCCTCCCGATAGGGCTGGGCCTGACCAAAAAT
ATACTGGGTTTCCTGTTTCCTTTTCTGATCATTCTTACAAGTTATACTCTTATTTGGAAG
GCCCTAAAGAAGGCTTATGAAATTCAGAAGAACAAACCAAGAAATGATGATATTTTTAAG
ATAATTATGGCAATTGTGCTTTTCTTTTTCTTTTCCTGGATTCCCCACCAAATATTCACT
TTTCTGGATGTATTGATTCAACTAGGCATCATACGTGACTGTAGAATTGCAGATATTGTG
GACACGGCCATGCCTATCACCATTTGTATAGCTTATTTTAACAATTGCCTGAATCCTCTT
TTTTATGGCTTTCTGGGGAAAAAATTTAAAAGATATTTTCTCCAGCTTCTAAAATATATT
CCCCCAAAAGCCAAATCCCACTCAAACCTTTCAACAAAAATGAGCACGCTTTCCTACCGC
CCCTCAGATAATGTAAGCTCATCCACCAAGAAGCCTGCACCATGTTTTGAGGTTGAGTGA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>angiotensin type I receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>angiotensin type II receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>bradykinin receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>angiotensin-activated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>kidney development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>low-density lipoprotein particle remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating angiotensin-activated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cholesterol esterification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of macrophage derived foam cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NAD(P)H oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phospholipase A2 activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of reactive oxygen species metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood vessel size by renin-angiotensin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of renal sodium excretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of systemic arterial blood pressure by renin-angiotensin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vasodilation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>renin-angiotensin regulation of aldosterone production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Rho protein signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="1">
      <id>BE0000215</id>
      <name>Peroxisome proliferator-activated receptor gamma</name>
      <organism>Humans</organism>
      <actions>
        <action>partial agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A6006</ref-id>
            <pubmed-id>19147680</pubmed-id>
            <citation>Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, Naruse M: A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology. 2009 Feb;150(2):862-70. doi: 10.1210/en.2008-0502. Epub 2009 Jan 15.</citation>
          </article>
          <article>
            <ref-id>A6007</ref-id>
            <pubmed-id>16938288</pubmed-id>
            <citation>Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K: Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res. 2006 Oct 1;72(1):184-90. Epub 2006 Jul 21.</citation>
          </article>
          <article>
            <ref-id>A6008</ref-id>
            <pubmed-id>18580862</pubmed-id>
            <citation>Kurtz TW: Beyond the classic angiotensin-receptor-blocker profile. Nat Clin Pract Cardiovasc Med. 2008 Jul;5 Suppl 1:S19-26. doi: 10.1038/ncpcardio0805.</citation>
          </article>
          <article>
            <ref-id>A6009</ref-id>
            <pubmed-id>15617852</pubmed-id>
            <citation>Yamagishi S, Takeuchi M: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses. 2005;64(3):476-8.</citation>
          </article>
          <article>
            <ref-id>A15408</ref-id>
            <pubmed-id>15868121</pubmed-id>
            <citation>Kurtz TW: Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol. 2005 Apr;42 Suppl 1:S9-16.</citation>
          </article>
          <article>
            <ref-id>A6010</ref-id>
            <pubmed-id>17691961</pubmed-id>
            <citation>Yamagishi S, Nakamura K, Matsui T: Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med. 2007 Aug;7(5):463-9.</citation>
          </article>
          <article>
            <ref-id>A15409</ref-id>
            <pubmed-id>16154710</pubmed-id>
            <citation>Yamagishi S, Takenaka K, Inoue H: Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation. Med Hypotheses. 2006;66(1):118-20. Epub 2005 Sep 12.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P37231" source="Swiss-Prot">
        <name>Peroxisome proliferator-activated receptor gamma</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels (By similarity).</specific-function>
        <gene-name>PPARG</gene-name>
        <locus>3p25</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.77</theoretical-pi>
        <molecular-weight>57619.58</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9236</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PPARG</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U79012</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1711117</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>595</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>595</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P37231</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PPARG_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NR1C3</synonym>
          <synonym>Nuclear receptor subfamily 1 group C member 3</synonym>
          <synonym>PPAR-gamma</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000429|Peroxisome proliferator-activated receptor gamma
MGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDLSVMEDHSHSF
DIKPFTTVDFSSISTPHYEDIPFTRTDPVVADYKYDLKLQEYQSAIKVEPASPPYYSEKT
QLYNKPHEEPSNSLMAIECRVCGDKASGFHYGVHACEGCKGFFRRTIRLKLIYDRCDLNC
RIHKKSRNKCQYCRFQKCLAVGMSHNAIRFGRMPQAEKEKLLAEISSDIDQLNPESADLR
ALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQE
QSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLAS
LMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVII
LSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQL
LQVIKKTETDMSLHPLLQEIYKDLY</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021642|Peroxisome proliferator-activated receptor gamma (PPARG)
ATGACCATGGTTGACACAGAGATGCCATTCTGGCCCACCAACTTTGGGATCAGCTCCGTG
GATCTCTCCGTAATGGAAGACCACTCCCACTCCTTTGATATCAAGCCCTTCACTACTGTT
GACTTCTCCAGCATTTCTACTCCACATTACGAAGACATTCCATTCACAAGAACAGATCCA
GTGGTTGCAGATTACAAGTATGACCTGAAACTTCAAGAGTACCAAAGTGCAATCAAAGTG
GAGCCTGCATCTCCACCTTATTATTCTGAGAAGACTCAGCTCTACAATAAGCCTCATGAA
GAGCCTTCCAACTCCCTCATGGCAATTGAATGTCGTGTCTGTGGAGATAAAGCTTCTGGA
TTTCACTATGGAGTTCATGCTTGTGAAGGATGCAAGGGTTTCTTCCGGAGAACAATCAGA
TTGAAGCTTATCTATGACAGATGTGATCTTAACTGTCGGATCCACAAAAAAAGTAGAAAT
AAATGTCAGTACTGTCGGTTTCAGAAATGCCTTGCAGTGGGGATGTCTCATAATGCCATC
AGGTTTGGGCGGATGCCACAGGCCGAGAAGGAGAAGCTGTTGGCGGAGATCTCCAGTGAT
ATCGACCAGCTGAATCCAGAGTCCGCTGACCTCCGGGCCCTGGCAAAACATTTGTATGAC
TCATACATAAAGTCCTTCCCGCTGACCAAAGCAAAGGCGAGGGCGATCTTGACAGGAAAG
ACAACAGACAAATCACCATTCGTTATCTATGACATGAATTCCTTAATGATGGGAGAAGAT
AAAATCAAGTTCAAACACATCACCCCCCTGCAGGAGCAGAGCAAAGAGGTGGCCATCCGC
ATCTTTCAGGGCTGCCAGTTTCGCTCCGTGGAGGCTGTGCAGGAGATCACAGAGTATGCC
AAAAGCATTCCTGGTTTTGTAAATCTTGACTTGAACGACCAAGTAACTCTCCTCAAATAT
GGAGTCCACGAGATCATTTACACAATGCTGGCCTCCTTGATGAATAAAGATGGGGTTCTC
ATATCCGAGGGCCAAGGCTTCATGACAAGGGAGTTTCTAAAGAGCCTGCGAAAGCCTTTT
GGTGACTTTATGGAGCCCAAGTTTGAGTTTGCTGTGAAGTTCAATGCACTGGAATTAGAT
GACAGCGACTTGGCAATATTTATTGCTGTCATTATTCTCAGTGGAGACCGCCCAGGTTTG
CTGAATGTGAAGCCCATTGAAGACATTCAAGACAACCTGCTACAAGCCCTGGAGCTCCAG
CTGAAGCTGAACCACCCTGAGTCCTCACAGCTGTTTGCCAAGCTGCTCCAGAAAATGACA
GACCTCAGACAGATTGTCACGGAACACGTGCAGCTACTGCAGGTGATCAAGAAGACGGAG
ACAGACATGAGTCTTCACCCGCTCCTGCAGGAGATCTACAAGGACTTGTACTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
          <pfam>
            <identifier>PF12577</identifier>
            <name>PPARgamma_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>RNA polymerase II transcription factor complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>activating transcription factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha-actinin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chromatin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>core promoter sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ligand-dependent nuclear receptor transcription coactivator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>prostaglandin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoid X receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II regulatory region DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription regulatory region DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of cysteine-type endopeptidase activity involved in apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brown fat cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell fate commitment</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hyperoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to insulin stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to lithium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to prostaglandin E stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to retinoic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to vitamin E</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>diet induced thermogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epithelial cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fatty acid oxidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucose homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoprotein transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>long-chain fatty acid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>low-density lipoprotein particle receptor biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of acute inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cholesterol storage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of collagen biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interferon-gamma-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of macrophage derived foam cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of pancreatic stellate cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of receptor biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of sequestering of triglyceride</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of smooth muscle cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of telomerase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organ regeneration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peroxisome proliferator activated receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>placenta development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fat cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fatty acid oxidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of oligodendrocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phagocytosis, engulfment</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of sequence-specific DNA binding transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cholesterol transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription involved in cell fate commitment</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to caffeine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cold</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to diuretic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estrogen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to immobilization stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to low-density lipoprotein particle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to mechanical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to metformin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nutrient</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to retinoic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to starvation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin A</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>rhythmic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>white fat cell differentiation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="5">
      <id>BE0003536</id>
      <name>Cytochrome P450 2C19</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A183299</ref-id>
            <pubmed-id>23516440</pubmed-id>
            <citation>Lake JE, Tseng CH, Currier JS: A pilot study of telmisartan for visceral adiposity in HIV infection: the metabolic abnormalities, telmisartan, and HIV infection (MATH) trial. PLoS One. 2013;8(3):e58135. doi: 10.1371/journal.pone.0058135. Epub 2013 Mar 14.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L3588</ref-id>
            <title>telmisartan - Drug Summary</title>
            <url>http://www.pdr.net/drug-summary/Micardis-telmisartan-1320</url>
          </link>
        </links>
        <attachments>
          <attachment>
            <ref-id>F1487</ref-id>
            <title>CTEP.gov CYP2C19 document</title>
            <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/487/original/cyp2c19.doc?1536956758</url>
          </attachment>
          <attachment>
            <ref-id>F1488</ref-id>
            <title>EMA label, Telmisartan</title>
            <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/488/original/EMA_label__telmisartan.pdf?1536956852</url>
          </attachment>
        </attachments>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P33261" source="Swiss-Prot">
        <name>Cytochrome P450 2C19</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.</specific-function>
        <gene-name>CYP2C19</gene-name>
        <locus>10q24.1-q24.3</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.42</theoretical-pi>
        <molecular-weight>55930.545</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2621</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M61854</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181344</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1328</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P33261</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2CJ_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>(R)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 7-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>CYPIIC17</synonym>
          <synonym>CYPIIC19</synonym>
          <synonym>Cytochrome P450-11A</synonym>
          <synonym>Cytochrome P450-254C</synonym>
          <synonym>Mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0020694|Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020695|Cytochrome P450 2C19 (CYP2C19)
ATGGATCCTTTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCAATCTGG
AGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA
AATATCCTACAGATAGATATTAAGGATGTCAGCAAATCCTTAACCAATCTCTCAAAAATC
TATGGCCCTGTGTTCACTCTGTATTTTGGCCTGGAACGCATGGTGGTGCTGCATGGATAT
GAAGTGGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCCATTTC
CCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATCGTTTTCAGCAATGGAAAGAGATGG
AAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
ATTATTTTCCAGAAACGTTTCGATTATAAAGATCAGCAATTTCTTAACTTGATGGAAAAA
TTGAATGAAAACATCAGGATTGTAAGCACCCCCTGGATCCAGATATGCAATAATTTTCCC
ACTATCATTGATTATTTCCCGGGAACCCATAACAAATTACTTAAAAACCTTGCTTTTATG
GAAAGTGATATTTTGGAGAAAGTAAAAGAACACCAAGAATCGATGGACATCAACAACCCT
CGGGACTTTATTGATTGCTTCCTGATCAAAATGGAGAAGGAAAAGCAAAACCAACAGTCT
GAATTCACTATTGAAAACTTGGTAATCACTGCAGCTGACTTACTTGGAGCTGGGACAGAG
ACAACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGAACGTGTCATTGGCAGAAACCGGAGCCCCTGCATGCAG
GACAGGGGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATCGAC
CTCATCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACGTTAAATTCAGAAACTACCTC
ATTCCCAAGGGCACAACCATATTAACTTCCCTCACTTCTGTGCTACATGACAACAAAGAA
TTTCCCAACCCAGAGATGTTTGACCCTCGTCACTTTCTGGATGAAGGTGGAAATTTTAAG
AAAAGTAACTACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAGGGCCTG
GCCCGCATGGAGCTGTTTTTATTCCTGACCTTCATTTTACAGAACTTTAACCTGAAATCT
CTGATTGACCCAAAGGACCTTGACACAACTCCTGTTGTCAATGGATTTGCTTCTGTCCCG
CCCTTCTATCAGCTGTGCTTCATTCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(R)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 7-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme position="7">
      <id>BE0003677</id>
      <name>UDP-glucuronosyltransferase 1-3</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A39946</ref-id>
            <pubmed-id>21691256</pubmed-id>
            <citation>Ieiri I, Nishimura C, Maeda K, Sasaki T, Kimura M, Chiyoda T, Hirota T, Irie S, Shimizu H, Noguchi T, Yoshida K, Sugiyama Y: Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet Genomics. 2011 Aug;21(8):495-505. doi: 10.1097/FPC.0b013e3283489ce2.</citation>
          </article>
          <article>
            <ref-id>A39947</ref-id>
            <pubmed-id>21829131</pubmed-id>
            <citation>Yamada A, Maeda K, Ishiguro N, Tsuda Y, Igarashi T, Ebner T, Roth W, Ikushiro S, Sugiyama Y: The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet Genomics. 2011 Sep;21(9):523-30. doi: 10.1097/FPC.0b013e3283482502.</citation>
          </article>
          <article>
            <ref-id>A39948</ref-id>
            <pubmed-id>22275465</pubmed-id>
            <citation>Gill KL, Houston JB, Galetin A: Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos. 2012 Apr;40(4):825-35. doi: 10.1124/dmd.111.043984. Epub 2012 Jan 24.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments>
          <attachment>
            <ref-id>F2102</ref-id>
            <title>DRUG-DRUG INTERACTIONS  FROM KNOWLEDGE BASE TO CLINICAL IMPACT</title>
            <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/102/original/Thesis_Marine_Andersson.pdf?1543427453</url>
          </attachment>
        </attachments>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P35503" source="Swiss-Prot">
        <name>UDP-glucuronosyltransferase 1-3</name>
        <general-function>Retinoic acid binding</general-function>
        <specific-function>UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.</specific-function>
        <gene-name>UGT1A3</gene-name>
        <locus>2q37</locus>
        <cellular-location>Microsome</cellular-location>
        <transmembrane-regions>492-508</transmembrane-regions>
        <signal-regions>1-28</signal-regions>
        <theoretical-pi>8.28</theoretical-pi>
        <molecular-weight>60337.835</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12535</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M84127</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>340135</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35503</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>UD13_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.4.1.17</synonym>
          <synonym>GNT1</synonym>
          <synonym>UDP-glucuronosyltransferase 1-C</synonym>
          <synonym>UDP-glucuronosyltransferase 1A3</synonym>
          <synonym>UDPGT 1-3</synonym>
          <synonym>UGT-1C</synonym>
          <synonym>UGT1</synonym>
          <synonym>UGT1C</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007065|UDP-glucuronosyltransferase 1-3
MATGLQVPLPWLATGLLLLLSVQPWAESGKVLVVPIDGSHWLSMREVLRELHARGHQAVV
LTPEVNMHIKEENFFTLTTYAISWTQDEFDRHVLGHTQLYFETEHFLKKFFRSMAMLNNM
SLVYHRSCVELLHNEALIRHLNATSFDVVLTDPVNLCAAVLAKYLSIPTVFFLRNIPCDL
DFKGTQCPNPSSYIPRLLTTNSDHMTFMQRVKNMLYPLALSYICHAFSAPYASLASELFQ
REVSVVDILSHASVWLFRGDFVMDYPRPIMPNMVFIGGINCANRKPLSQEFEAYINASGE
HGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQND
LLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMT
SEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAH
DLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017182|UDP-glucuronosyltransferase 1-3 (UGT1A3)
ATGGCCACAGGACTCCAGGTTCCCCTGCCGTGGCTGGCCACAGGACTGCTGCTTCTCCTC
AGTGTCCAGCCCTGGGCTGAGAGTGGAAAGGTGTTGGTGGTGCCCATTGATGGCAGCCAC
TGGCTCAGCATGCGGGAGGTCTTGCGGGAGCTCCATGCCAGAGGCCACCAGGCAGTGGTC
CTCACCCCAGAGGTGAATATGCACATCAAAGAAGAGAACTTTTTCACCCTGACAACCTAT
GCCATTTCGTGGACCCAGGATGAATTTGATCGCCATGTGCTGGGCCACACTCAACTGTAC
TTTGAAACAGAACATTTTCTGAAGAAATTTTTCAGAAGTATGGCAATGTTGAACAATATG
TCTTTGGTCTATCATAGGTCTTGTGTGGAGCTACTACATAATGAGGCCCTGATCAGGCAC
CTGAATGCTACTTCCTTTGATGTGGTTTTAACAGACCCCGTTAACCTCTGCGCGGCAGTG
CTGGCTAAGTACCTGTCGATTCCTACTGTGTTTTTTTTGAGGAACATTCCATGTGATTTA
GACTTTAAGGGCACACAGTGTCCAAACCCTTCCTCCTATATTCCTAGATTACTAACAACC
AATTCAGACCACATGACATTCATGCAAAGGGTCAAGAACATGCTCTACCCTCTGGCCCTG
TCCTACATTTGCCATGCTTTTTCTGCTCCTTATGCAAGCCTTGCCTCTGAGCTTTTTCAG
AGAGAGGTGTCAGTGGTGGATATTCTCAGTCATGCATCTGTGTGGCTGTTCCGAGGGGAC
TTTGTGATGGACTACCCCAGGCCAATCATGCCCAACATGGTCTTCATTGGGGGCATCAAC
TGTGCCAACAGGAAGCCACTATCTCAGGAATTTGAAGCCTACATTAATGCTTCTGGAGAA
CATGGAATTGTGGTTTTCTCTTTGGGATCAATGGTCTCAGAAATTCCAGAGAAGAAAGCT
ATGGCAATTGCTGATGCTTTGGGCAAAATCCCTCAGACAGTCCTGTGGCGGTACACTGGA
ACCCGACCATCGAATCTTGCGAACAACACGATACTTGTTAAGTGGCTACCCCAAAACGAT
CTGCTTGGTCACCCGATGACCCGTGCCTTTATCACCCATGCTGGTTCCCATGGTGTTTAT
GAAAGCATATGCAATGGCGTTCCCATGGTGATGATGCCCTTGTTTGGTGATCAGATGGAC
AATGCAAAGCGCATGGAGACTAAGGGAGCTGGAGTGACCCTGAATGTTCTGGAAATGACT
TCTGAAGATTTAGAAAATGCTCTAAAAGCAGTCATCAATGACAAAAGTTACAAGGAGAAC
ATCATGCGCCTCTCCAGCCTTCACAAGGACCGCCCGGTGGAGCCGCTGGACCTGGCCGTG
TTCTGGGTGGAGTTTGTGATGAGGCACAAGGGCGCGCCACACCTGCGCCCCGCAGCCCAC
GACCTCACCTGGTACCAGTACCATTCCTTGGACGTGATTGGTTTCCTCTTGGCCGTCGTG
CTGACAGTGGCCTTCATCACCTTTAAATGTTGTGCTTATGGCTACCGGAAATGCTTGGGG
AAAAAAGGGCGAGTTAAGAAAGCCCACAAATCCAAGACCCATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00201</identifier>
            <name>UDPGT</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucuronosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cellular glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of fatty acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of glucuronosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinoic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic glucuronidation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters>
    <transporter position="2">
      <id>BE0001032</id>
      <name>P-glycoprotein 1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16013</ref-id>
            <pubmed-id>20222053</pubmed-id>
            <citation>Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08183" source="Swiss-Prot">
        <name>Multidrug resistance protein 1</name>
        <general-function>Xenobiotic-transporting atpase activity</general-function>
        <specific-function>Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.</specific-function>
        <gene-name>ABCB1</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>45-67
117-137
187-208
216-236
293-316
331-352
712-732
757-777
833-853
855-874
935-957
974-995</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.44</theoretical-pi>
        <molecular-weight>141477.255</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:40</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCB1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M14758</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>307180</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08183</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MDR1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.6.3.44</synonym>
          <synonym>ATP-binding cassette sub-family B member 1</synonym>
          <synonym>MDR1</synonym>
          <synonym>P-glycoprotein 1</synonym>
          <synonym>PGY1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037114|Multidrug resistance protein 1
MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII
HGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG
IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS
KINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT
DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG
AAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG
AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG
QTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF
ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA
IARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG
FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS
SLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII
NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA
GEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI
ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEA
IENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG
AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS
YSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV
QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV
SQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD
EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL
LAQKGIYFSMVSVQAGTKRQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016291|Multidrug resistance protein 1 (ABCB1)
ATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC
AATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT
CGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC
CATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA
AATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT
ACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA
ATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT
GGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA
GGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCC
AAGATTAATGAAGGAATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT
TTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC
ATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT
GATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA
ATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT
TTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT
GCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG
GTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT
GGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA
GCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG
AGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT
TACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGTCTGAACCTGAAGGTGCAGAGTGGG
CAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG
CAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC
ATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT
GCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT
GAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT
GACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC
ATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC
TTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG
ACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT
TTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC
ATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA
GCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC
AGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA
AAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT
ATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA
AATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA
AGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA
GCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT
GGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT
GTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT
GATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA
GCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA
CTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT
GGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTTCTGGGAAGATCGCTACTGAAGCA
ATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT
GCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT
ACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA
GCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT
GTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA
GCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC
TACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT
GTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG
AAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC
CAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA
ATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC
ATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG
TCACAGGAAGAGATTGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA
CTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG
AAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT
GAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA
GCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA
GACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG
CTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>xenobiotic-transporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G2/M transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>stem cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="3">
      <id>BE0001069</id>
      <name>Canalicular multispecific organic anion transporter 1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16013</ref-id>
            <pubmed-id>20222053</pubmed-id>
            <citation>Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q92887" source="Swiss-Prot">
        <name>Canalicular multispecific organic anion transporter 1</name>
        <general-function>Organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.</specific-function>
        <gene-name>ABCC2</gene-name>
        <locus>10q24</locus>
        <cellular-location>Apical cell membrane</cellular-location>
        <transmembrane-regions>28-48
69-89
94-114
127-147
166-186
314-334
361-381
438-458
462-482
545-565
588-608
972-992
1034-1054
1098-1118
1120-1140
1212-1232
1235-1255</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.46</theoretical-pi>
        <molecular-weight>174205.64</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:53</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCC2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U63970</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1764162</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>780</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q92887</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MRP2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ATP-binding cassette sub-family C member 2</synonym>
          <synonym>Canalicular multidrug resistance protein</synonym>
          <synonym>CMOAT</synonym>
          <synonym>CMOAT1</synonym>
          <synonym>CMRP</synonym>
          <synonym>MRP2</synonym>
          <synonym>Multidrug resistance-associated protein 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010748|Canalicular multispecific organic anion transporter 1
MLEKFCNSTFWNSSFLDSPEADLPLCFEQTVLVWIPLGYLWLLAPWQLLHVYKSRTKRSS
TTKLYLAKQVFVGFLLILAAIELALVLTEDSGQATVPAVRYTNPSLYLGTWLLVLLIQYS
RQWCVQKNSWFLSLFWILSILCGTFQFQTLIRTLLQGDNSNLAYSCLFFISYGFQILILI
FSAFSENNESSNNPSSIASFLSSITYSWYDSIILKGYKRPLTLEDVWEVDEEMKTKTLVS
KFETHMKRELQKARRALQRRQEKSSQQNSGARLPGLNKNQSQSQDALVLEDVEKKKKKSG
TKKDVPKSWLMKALFKTFYMVLLKSFLLKLVNDIFTFVSPQLLKLLISFASDRDTYLWIG
YLCAILLFTAALIQSFCLQCYFQLCFKLGVKVRTAIMASVYKKALTLSNLARKEYTVGET
VNLMSVDAQKLMDVTNFMHMLWSSVLQIVLSIFFLWRELGPSVLAGVGVMVLVIPINAIL
STKSKTIQVKNMKNKDKRLKIMNEILSGIKILKYFAWEPSFRDQVQNLRKKELKNLLAFS
QLQCVVIFVFQLTPVLVSVVTFSVYVLVDSNNILDAQKAFTSITLFNILRFPLSMLPMMI
SSMLQASVSTERLEKYLGGDDLDTSAIRHDCNFDKAMQFSEASFTWEHDSEATVRDVNLD
IMAGQLVAVIGPVGSGKSSLISAMLGEMENVHGHITIKGTTAYVPQQSWIQNGTIKDNIL
FGTEFNEKRYQQVLEACALLPDLEMLPGGDLAEIGEKGINLSGGQKQRISLARATYQNLD
IYLLDDPLSAVDAHVGKHIFNKVLGPNGLLKGKTRLLVTHSMHFLPQVDEIVVLGNGTIV
EKGSYSALLAKKGEFAKNLKTFLRHTGPEEEATVHDGSEEEDDDYGLISSVEEIPEDAAS
ITMRRENSFRRTLSRSSRSNGRHLKSLRNSLKTRNVNSLKEDEELVKGQKLIKKEFIETG
KVKFSIYLEYLQAIGLFSIFFIILAFVMNSVAFIGSNLWLSAWTSDSKIFNSTDYPASQR
DMRVGVYGALGLAQGIFVFIAHFWSAFGFVHASNILHKQLLNNILRAPMRFFDTTPTGRI
VNRFAGDISTVDDTLPQSLRSWITCFLGIISTLVMICMATPVFTIIVIPLGIIYVSVQMF
YVSTSRQLRRLDSVTRSPIYSHFSETVSGLPVIRAFEHQQRFLKHNEVRIDTNQKCVFSW
ITSNRWLAIRLELVGNLTVFFSALMMVIYRDTLSGDTVGFVLSNALNITQTLNWLVRMTS
EIETNIVAVERITEYTKVENEAPWVTDKRPPPDWPSKGKIQFNNYQVRYRPELDLVLRGI
TCDIGSMEKIGVVGRTGAGKSSLTNCLFRILEAAGGQIIIDGVDIASIGLHDLREKLTII
PQDPILFSGSLRMNLDPFNNYSDEEIWKALELAHLKSFVASLQLGLSHEVTEAGGNLSIG
QRQLLCLGRALLRKSKILVLDEATAAVDLETDNLIQTTIQNEFAHCTVITIAHRLHTIMD
SDKVMVLDNGKIIECGSPEELLQIPGPFYFMAKEAGIENVNSTKF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010749|Canalicular multispecific organic anion transporter 1 (ABCC2)
ATGCTGGAGAAGTTCTGCAACTCTACTTTTTGGAATTCCTCATTCCTGGACAGTCCGGAG
GCAGACCTGCCACTTTGTTTTGAGCAAACTGTTCTGGTGTGGATTCCCTTGGGCTTCCTA
TGGCTCCTGGCCCCCTGGCAGCTTCTCCACGTGTATAAATCCAGGACCAAGAGATCCTCT
ACCACCAAACTCTATCTTGCTAAGCAGGTATTCGTTGGTTTTCTTCTTATTCTAGCAGCC
ATAGAGCTGGCCCTTGTACTCACAGAAGACTCTGGACAAGCCACAGTCCCTGCTGTTCGA
TATACCAATCCAAGCCTCTACCTAGGCACATGGCTCCTGGTTTTGCTGATCCAATACAGC
AGACAATGGTGTGTACAGAAAAACTCCTGGTTCCTGTCCCTATTCTGGATTCTCTCGATA
CTCTGTGGCACTTTCCAATTTCAGACTCTGATCCGGACACTCTTACAGGGTGACAATTCT
AATCTAGCCTACTCCTGCCTGTTCTTCATCTCCTACGGATTCCAGATCCTGATCCTGATC
TTTTCAGCATTTTCAGAAAATAATGAGTCATCAAATAATCCATCATCCATAGCTTCATTC
CTGAGTAGCATTACCTACAGCTGGTATGACAGCATCATTCTGAAAGGCTACAAGCGTCCT
CTGACACTCGAGGATGTCTGGGAAGTTGATGAAGAGATGAAAACCAAGACATTAGTGAGC
AAGTTTGAAACGCACATGAAGAGAGAGCTGCAGAAAGCCAGGCGGGCACTCCAGAGACGG
CAGGAGAAGAGCTCCCAGCAGAACTCTGGAGCCAGGCTGCCTGGCTTGAACAAGAATCAG
AGTCAAAGCCAAGATGCCCTTGTCCTGGAAGATGTTGAAAAGAAAAAAAAGAAGTCTGGG
ACCAAAAAAGATGTTCCAAAATCCTGGTTGATGAAGGCTCTGTTCAAAACTTTCTACATG
GTGCTCCTGAAATCATTCCTACTGAAGCTAGTGAATGACATCTTCACGTTTGTGAGTCCT
CAGCTGCTGAAATTGCTGATCTCCTTTGCAAGTGACCGTGACACATATTTGTGGATTGGA
TATCTCTGTGCAATCCTCTTATTCACTGCGGCTCTCATTCAGTCTTTCTGCCTTCAGTGT
TATTTCCAACTGTGCTTCAAGCTGGGTGTAAAAGTACGGACAGCTATCATGGCTTCTGTA
TATAAGAAGGCATTGACCCTATCCAACTTGGCCAGGAAGGAGTACACCGTTGGAGAAACA
GTGAACCTGATGTCTGTGGATGCCCAGAAGCTCATGGATGTGACCAACTTCATGCACATG
CTGTGGTCAAGTGTTCTACAGATTGTCTTATCTATCTTCTTCCTATGGAGAGAGTTGGGA
CCCTCAGTCTTAGCAGGTGTTGGGGTGATGGTGCTTGTAATCCCAATTAATGCGATACTG
TCCACCAAGAGTAAGACCATTCAGGTCAAAAATATGAAGAATAAAGACAAACGTTTAAAG
ATCATGAATGAGATTCTTAGTGGAATCAAGATCCTGAAATATTTTGCCTGGGAACCTTCA
TTCAGAGACCAAGTACAAAACCTCCGGAAGAAAGAGCTCAAGAACCTGCTGGCCTTTAGT
CAACTACAGTGTGTAGTAATATTCGTCTTCCAGTTAACTCCAGTCCTGGTATCTGTGGTC
ACATTTTCTGTTTATGTCCTGGTGGATAGCAACAATATTTTGGATGCACAAAAGGCCTTC
ACCTCCATTACCCTCTTCAATATCCTGCGCTTTCCCCTGAGCATGCTTCCCATGATGATC
TCCTCCATGCTCCAGGCCAGTGTTTCCACAGAGCGGCTAGAGAAGTACTTGGGAGGGGAT
GACTTGGACACATCTGCCATTCGACATGACTGCAATTTTGACAAAGCCATGCAGTTTTCT
GAGGCCTCCTTTACCTGGGAACATGATTCGGAAGCCACAGTCCGAGATGTGAACCTGGAC
ATTATGGCAGGCCAACTTGTGGCTGTGATAGGCCCTGTCGGCTCTGGGAAATCCTCCTTG
ATATCAGCCATGCTGGGAGAAATGGAAAATGTCCACGGGCACATCACCATCAAGGGCACC
ACTGCCTATGTCCCACAGCAGTCCTGGATTCAGAATGGCACCATAAAGGACAACATCCTT
TTTGGAACAGAGTTTAATGAAAAGAGGTACCAGCAAGTACTGGAGGCCTGTGCTCTCCTC
CCAGACTTGGAAATGCTGCCTGGAGGAGATTTGGCTGAGATTGGAGAGAAGGGTATAAAT
CTTAGTGGGGGTCAGAAGCAGCGGATCAGCCTGGCCAGAGCTACCTACCAAAATTTAGAC
ATCTATCTTCTAGATGACCCCCTGTCTGCAGTGGATGCTCATGTAGGAAAACATATTTTT
AATAAGGTCTTGGGCCCCAATGGCCTGTTGAAAGGCAAGACTCGACTCTTGGTTACACAT
AGCATGCACTTTCTTCCTCAAGTGGATGAGATTGTAGTTCTGGGGAATGGAACAATTGTA
GAGAAAGGATCCTACAGTGCTCTCCTGGCCAAAAAAGGAGAGTTTGCTAAGAATCTGAAG
ACATTTCTAAGACATACAGGCCCTGAAGAGGAAGCCACAGTCCATGATGGCAGTGAAGAA
GAAGACGATGACTATGGGCTGATATCCAGTGTGGAAGAGATCCCCGAAGATGCAGCCTCC
ATAACCATGAGAAGAGAGAACAGCTTTCGTCGAACACTTAGCCGCAGTTCTAGGTCCAAT
GGCAGGCATCTGAAGTCCCTGAGAAACTCCTTGAAAACTCGGAATGTGAATAGCCTGAAG
GAAGACGAAGAACTAGTGAAAGGACAAAAACTAATTAAGAAGGAATTCATAGAAACTGGA
AAGGTGAAGTTCTCCATCTACCTGGAGTACCTACAAGCAATAGGATTGTTTTCGATATTC
TTCATCATCCTTGCGTTTGTGATGAATTCTGTGGCTTTTATTGGATCCAACCTCTGGCTC
AGTGCTTGGACCAGTGACTCTAAAATCTTCAATAGCACCGACTATCCAGCATCTCAGAGG
GACATGAGAGTTGGAGTCTACGGAGCTCTGGGATTAGCCCAAGGTATATTTGTGTTCATA
GCACATTTCTGGAGTGCCTTTGGTTTCGTCCATGCATCAAATATCTTGCACAAGCAACTG
CTGAACAATATCCTTCGAGCACCTATGAGATTTTTTGACACAACACCCACAGGCCGGATT
GTGAACAGGTTTGCCGGCGATATTTCCACAGTGGATGACACCCTGCCTCAGTCCTTGCGC
AGCTGGATTACATGCTTCCTGGGGATAATCAGCACCCTTGTCATGATCTGCATGGCCACT
CCTGTCTTCACCATCATCGTCATTCCTCTTGGCATTATTTATGTATCTGTTCAGATGTTT
TATGTGTCTACCTCCCGCCAGCTGAGGCGTCTGGACTCTGTCACCAGGTCCCCAATCTAC
TCTCACTTCAGCGAGACCGTATCAGGTTTGCCAGTTATCCGTGCCTTTGAGCACCAGCAG
CGATTTCTGAAACACAATGAGGTGAGGATTGACACCAACCAGAAATGTGTCTTTTCCTGG
ATCACCTCCAACAGGTGGCTTGCAATTCGCCTGGAGCTGGTTGGGAACCTGACTGTCTTC
TTTTCAGCCTTGATGATGGTTATTTATAGAGATACCCTAAGTGGGGACACTGTTGGCTTT
GTTCTGTCCAATGCACTCAATATCACACAAACCCTGAACTGGCTGGTGAGGATGACATCA
GAAATAGAGACCAACATTGTGGCTGTTGAGCGAATAACTGAGTACACAAAAGTGGAAAAT
GAGGCACCCTGGGTGACTGATAAGAGGCCTCCGCCAGATTGGCCCAGCAAAGGCAAGATC
CAGTTTAACAACTACCAAGTGCGGTACCGACCTGAGCTGGATCTGGTCCTCAGAGGGATC
ACTTGTGACATCGGTAGCATGGAGAAGATTGGTGTGGTGGGCAGGACAGGAGCTGGAAAG
TCATCCCTCACAAACTGCCTCTTCAGAATCTTAGAGGCTGCCGGTGGTCAGATTATCATT
GATGGAGTAGATATTGCTTCCATTGGGCTCCACGACCTCCGAGAGAAGCTGACCATCATC
CCCCAGGACCCCATCCTGTTCTCTGGAAGCCTGAGGATGAATCTCGACCCTTTCAACAAC
TACTCAGATGAGGAGATTTGGAAGGCCTTGGAGCTGGCTCACCTCAAGTCTTTTGTGGCC
AGCCTGCAACTTGGGTTATCCCACGAAGTGACAGAGGCTGGTGGCAACCTGAGCATAGGC
CAGAGGCAGCTGCTGTGCCTGGGCAGGGCTCTGCTTCGGAAATCCAAGATCCTGGTCCTG
GATGAGGCCACTGCTGCGGTGGATCTAGAGACAGACAACCTCATTCAGACGACCATCCAA
AACGAGTTCGCCCACTGCACAGTGATCACCATCGCCCACAGGCTGCACACCATCATGGAC
AGTGACAAGGTAATGGTCCTAGACAACGGGAAGATTATAGAGTGCGGCAGCCCTGAAGAA
CTGCTACAAATCCCTGGACCCTTTTACTTTATGGCTAAGGAAGCTGGCATTGAGAATGTG
AACAGCACAAAATTCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular chloride ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostaglandin transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to arsenic-containing substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estrogen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to heat</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to methotrexate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to oxidative stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thyroid hormone transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="4">
      <id>BE0001067</id>
      <name>ATP-binding cassette sub-family G member 2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16013</ref-id>
            <pubmed-id>20222053</pubmed-id>
            <citation>Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9UNQ0" source="Swiss-Prot">
        <name>ATP-binding cassette sub-family G member 2</name>
        <general-function>Xenobiotic-transporting atpase activity</general-function>
        <specific-function>High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. Implicated in the efflux of numerous drugs and xenobiotics: mitoxantrone, the photosensitizer pheophorbide, camptothecin, methotrexate, azidothymidine (AZT), and the anthracyclines daunorubicin and doxorubicin.</specific-function>
        <gene-name>ABCG2</gene-name>
        <locus>4q22</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>396-416
429-449
478-498
507-527
536-556
631-651</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.9</theoretical-pi>
        <molecular-weight>72313.47</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:74</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCG2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF103796</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4185796</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>792</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9UNQ0</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ABCG2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ABCP</synonym>
          <synonym>BCRP</synonym>
          <synonym>BCRP1</synonym>
          <synonym>Breast cancer resistance protein</synonym>
          <synonym>CDw338</synonym>
          <synonym>Mitoxantrone resistance-associated protein</synonym>
          <synonym>MXR</synonym>
          <synonym>Placenta-specific ATP-binding cassette transporter</synonym>
          <synonym>Urate exporter</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002125|ATP-binding cassette sub-family G member 2
MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKSGFLPCRKPVE
KEILSNINGIMKPGLNAILGPTGGGKSSLLDVLAARKDPSGLSGDVLINGAPRPANFKCN
SGYVVQDDVVMGTLTVRENLQFSAALRLATTMTNHEKNERINRVIQELGLDKVADSKVGT
QFIRGVSGGERKRTSIGMELITDPSILFLDEPTTGLDSSTANAVLLLLKRMSKQGRTIIF
SIHQPRYSIFKLFDSLTLLASGRLMFHGPAQEALGYFESAGYHCEAYNNPADFFLDIING
DSTAVALNREEDFKATEIIEPSKQDKPLIEKLAEIYVNSSFYKETKAELHQLSGGEKKKK
ITVFKEISYTTSFCHQLRWVSKRSFKNLLGNPQASIAQIIVTVVLGLVIGAIYFGLKNDS
TGIQNRAGVLFFLTTNQCFSSVSAVELFVVEKKLFIHEYISGYYRVSSYFLGKLLSDLLP
MRMLPSIIFTCIVYFMLGLKPKADAFFVMMFTLMMVAYSASSMALAIAAGQSVVSVATLL
MTICFVFMMIFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFCPGLNATGN
NPCNYATCTGEEYLVKQGIDLSPWGLWKNHVALACMIVIFLTIAYLKLLFLKKYS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016303|ATP-binding cassette sub-family G member 2 (ABCG2)
ATGTCTTCCAGTAATGTCGAAGTTTTTATCCCAGTGTCACAAGGAAACACCAATGGCTTC
CCCGCGACAGCTTCCAATGACCTGAAGGCATTTACTGAAGGAGCTGTGTTAAGTTTTCAT
AACATCTGCTATCGAGTAAAACTGAAGAGTGGCTTTCTACCTTGTCGAAAACCAGTTGAG
AAAGAAATATTATCGAATATCAATGGGATCATGAAACCTGGTCTCAACGCCATCCTGGGA
CCCACAGGTGGAGGCAAATCTTCGTTATTAGATGTCTTAGCTGCAAGGAAAGATCCAAGT
GGATTATCTGGAGATGTTCTGATAAATGGAGCACCGCGACCTGCCAATTTCAAATGTAAT
TCAGGTTACGTGGTACAAGATGATGTTGTGATGGGCACTCTGACGGTGAGAGAAAACTTA
CAGTTCTCAGCAGCTCTTCGGCTTGCAACAACTATGACGAATCATGAAAAAAACGAACGG
ATTAACAGGGTCATTCAAGAGTTAGGTCTGGATAAAGTGGCAGACTCCAAGGTTGGAACT
CAGTTTATCCGTGGTGTGTCTGGAGGAGAAAGAAAAAGGACTAGTATAGGAATGGAGCTT
ATCACTGATCCTTCCATCTTGTTCTTGGATGAGCCTACAACTGGCTTAGACTCAAGCACA
GCAAATGCTGTCCTTTTGCTCCTGAAAAGGATGTCTAAGCAGGGACGAACAATCATCTTC
TCCATTCATCAGCCTCGATATTCCATCTTCAAGTTGTTTGATAGCCTCACCTTATTGGCC
TCAGGAAGACTTATGTTCCACGGGCCTGCTCAGGAGGCCTTGGGATACTTTGAATCAGCT
GGTTATCACTGTGAGGCCTATAATAACCCTGCAGACTTCTTCTTGGACATCATTAATGGA
GATTCCACTGCTGTGGCATTAAACAGAGAAGAAGACTTTAAAGCCACAGAGATCATAGAG
CCTTCCAAGCAGGATAAGCCACTCATAGAAAAATTAGCGGAGATTTATGTCAACTCCTCC
TTCTACAAAGAGACAAAAGCTGAATTACATCAACTTTCCGGGGGTGAGAAGAAGAAGAAG
ATCACAGTCTTCAAGGAGATCAGCTACACCACCTCCTTCTGTCATCAACTCAGATGGGTT
TCCAAGCGTTCATTCAAAAACTTGCTGGGTAATCCCCAGGCCTCTATAGCTCAGATCATT
GTCACAGTCGTACTGGGACTGGTTATAGGTGCCATTTACTTTGGGCTAAAAAATGATTCT
ACTGGAATCCAGAACAGAGCTGGGGTTCTCTTCTTCCTGACGACCAACCAGTGTTTCAGC
AGTGTTTCAGCCGTGGAACTCTTTGTGGTAGAGAAGAAGCTCTTCATACATGAATACATC
AGCGGATACTACAGAGTGTCATCTTATTTCCTTGGAAAACTGTTATCTGATTTATTACCC
ATGAGGATGTTACCAAGTATTATATTTACCTGTATAGTGTACTTCATGTTAGGATTGAAG
CCAAAGGCAGATGCCTTCTTCGTTATGATGTTTACCCTTATGATGGTGGCTTATTCAGCC
AGTTCCATGGCACTGGCCATAGCAGCAGGTCAGAGTGTGGTTTCTGTAGCAACACTTCTC
ATGACCATCTGTTTTGTGTTTATGATGGTCTGTTGGTCAATCTCACAACCATTGCATCTT
GGCTGTCATGGCTTCAGTACTTCAGCATTCCACGATATGGATTTACGGCTTTGCAGCATA
ATGAATTTTTGGGACAAAACTTCTGCCCAGGACTCAATGCAACAGGAAACAATCCTTGTA
ACTATGCAACATGTACTGGCGAAGAATATTTGGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF01061</identifier>
            <name>ABC2_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>xenobiotic-transporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular iron ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heme transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>urate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="6">
      <id>BE0000703</id>
      <name>Bile salt export pump</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A33345</ref-id>
            <pubmed-id>24014644</pubmed-id>
            <citation>Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="O95342" source="Swiss-Prot">
        <name>Bile salt export pump</name>
        <general-function>Transporter activity</general-function>
        <specific-function>Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.</specific-function>
        <gene-name>ABCB11</gene-name>
        <locus>2q24</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>63-83
148-168
216-236
241-261
320-340
354-374
756-776
795-815
870-890
891-911
980-1000
1012-1032</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.52</theoretical-pi>
        <molecular-weight>146405.83</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:42</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCB11</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF091582</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3873243</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>778</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O95342</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ABCBB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ATP-binding cassette sub-family B member 11</synonym>
          <synonym>BSEP</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010492|Bile salt export pump
MSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVGFFQLFRFSSSTDIW
LMFVGSLCAFLHGIAQPGVLLIFGTMTDVFIDYDVELQELQIPGKACVNNTIVWTNSSLN
QNMTNGTRCGLLNIESEMIKFASYYAGIAVAVLITGYIQICFWVIAAARQIQKMRKFYFR
RIMRMEIGWFDCNSVGELNTRFSDDINKINDAIADQMALFIQRMTSTICGFLLGFFRGWK
LTLVIISVSPLIGIGAATIGLSVSKFTDYELKAYAKAGVVADEVISSMRTVAAFGGEKRE
VERYEKNLVFAQRWGIRKGIVMGFFTGFVWCLIFLCYALAFWYGSTLVLDEGEYTPGTLV
QIFLSVIVGALNLGNASPCLEAFATGRAAATSIFETIDRKPIIDCMSEDGYKLDRIKGEI
EFHNVTFHYPSRPEVKILNDLNMVIKPGEMTALVGPSGAGKSTALQLIQRFYDPCEGMVT
VDGHDIRSLNIQWLRDQIGIVEQEPVLFSTTIAENIRYGREDATMEDIVQAAKEANAYNF
IMDLPQQFDTLVGEGGGQMSGGQKQRVAIARALIRNPKILLLDMATSALDNESEAMVQEV
LSKIQHGHTIISVAHRLSTVRAADTIIGFEHGTAVERGTHEELLERKGVYFTLVTLQSQG
NQALNEEDIKDATEDDMLARTFSRGSYQDSLRASIRQRSKSQLSYLVHEPPLAVVDHKST
YEEDRKDKDIPVQEEVEPAPVRRILKFSAPEWPYMLVGSVGAAVNGTVTPLYAFLFSQIL
GTFSIPDKEEQRSQINGVCLLFVAMGCVSLFTQFLQGYAFAKSGELLTKRLRKFGFRAML
GQDIAWFDDLRNSPGALTTRLATDASQVQGAAGSQIGMIVNSFTNVTVAMIIAFSFSWKL
SLVILCFFPFLALSGATQTRMLTGFASRDKQALEMVGQITNEALSNIRTVAGIGKERRFI
EALETELEKPFKTAIQKANIYGFCFAFAQCIMFIANSASYRYGGYLISNEGLHFSYVFRV
ISAVVLSATALGRAFSYTPSYAKAKISAARFFQLLDRQPPISVYNTAGEKWDNFQGKIDF
VDCKFTYPSRPDSQVLNGLSVSISPGQTLAFVGSSGCGKSTSIQLLERFYDPDQGKVMID
GHDSKKVNVQFLRSNIGIVSQEPVLFACSIMDNIKYGDNTKEIPMERVIAAAKQAQLHDF
VMSLPEKYETNVGSQGSQLSRGEKQRIAIARAIVRDPKILLLDEATSALDTESEKTVQVA
LDKAREGRTCIVIAHRLSTIQNADIIAVMAQGVVIEKGTHEELMAQKGAYYKLVTTGSPI
S</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010493|Bile salt export pump (ABCB11)
ATGTCTGACTCAGTAATTCTTCGAAGTATAAAGAAATTTGGAGAGGAGAATGATGGTTTT
GAGTCAGATAAATCATATAATAATGATAAGAAATCAAGGTTACAAGATGAGAAGAAAGGT
GATGGCGTTAGAGTTGGCTTCTTTCAATTGTTTCGGTTTTCTTCATCAACTGACATTTGG
CTGATGTTTGTGGGAAGTTTGTGTGCATTTCTCCATGGAATAGCCCAGCCAGGCGTGCTA
CTCATTTTTGGCACAATGACAGATGTTTTTATTGACTACGACGTTGAGTTACAAGAACTC
CAGATTCCAGGAAAAGCATGTGTGAATAACACCATTGTATGGACTAACAGTTCCCTCAAC
CAGAACATGACAAATGGAACACGTTGTGGGTTGCTGAACATCGAGAGCGAAATGATCAAA
TTTGCCAGTTACTATGCTGGAATTGCTGTCGCAGTACTTATCACAGGATATATTCAAATA
TGCTTTTGGGTCATTGCCGCAGCTCGTCAGATACAGAAAATGAGAAAATTTTACTTTAGG
AGAATAATGAGAATGGAAATAGGGTGGTTTGACTGCAATTCAGTGGGGGAGCTGAATACA
AGATTCTCTGATGATATTAATAAAATCAATGATGCCATAGCTGACCAAATGGCCCTTTTC
ATTCAGCGCATGACCTCGACCATCTGTGGTTTCCTGTTGGGATTTTTCAGGGGTTGGAAA
CTGACCTTGGTTATTATTTCTGTCAGCCCTCTCATTGGGATTGGAGCAGCCACCATTGGT
CTGAGTGTGTCCAAGTTTACGGACTATGAGCTGAAGGCCTATGCCAAAGCAGGGGTGGTG
GCTGATGAAGTCATTTCATCAATGAGAACAGTGGCTGCTTTTGGTGGTGAGAAAAGAGAG
GTTGAAAGGTATGAGAAAAATCTTGTGTTCGCCCAGCGTTGGGGAATTAGAAAAGGAATA
GTGATGGGATTCTTTACTGGATTCGTGTGGTGTCTCATCTTTTTGTGTTATGCACTGGCC
TTCTGGTACGGCTCCACACTTGTCCTGGATGAAGGAGAATATACACCAGGAACCCTTGTC
CAGATTTTCCTCAGTGTCATAGTAGGAGCTTTAAATCTTGGCAATGCCTCTCCTTGTTTG
GAAGCCTTTGCAACTGGACGTGCAGCAGCCACCAGCATTTTTGAGACAATAGACAGGAAA
CCCATCATTGACTGCATGTCAGAAGATGGTTACAAGTTGGATCGAATCAAGGGTGAAATT
GAATTCCATAATGTGACCTTCCATTATCCTTCCAGACCAGAGGTGAAGATTCTAAATGAC
CTCAACATGGTCATTAAACCAGGGGAAATGACAGCTCTGGTAGGACCCAGTGGAGCTGGA
AAAAGTACAGCACTGCAACTCATTCAGCGATTCTATGACCCCTGTGAAGGAATGGTGACC
GTGGATGGCCATGACATTCGCTCTCTTAACATTCAGTGGCTTAGAGATCAGATTGGGATA
GTGGAGCAAGAGCCAGTTCTGTTCTCTACCACCATTGCAGAAAATATTCGCTATGGCAGA
GAAGATGCAACAATGGAAGACATAGTCCAAGCTGCCAAGGAGGCCAATGCCTACAACTTC
ATCATGGACCTGCCACAGCAATTTGACACCCTTGTTGGAGAAGGAGGAGGCCAGATGAGT
GGTGGCCAGAAACAAAGGGTAGCTATCGCCAGAGCCCTCATCCGAAATCCCAAGATTCTG
CTTTTGGACATGGCCACCTCAGCTCTGGACAATGAGAGTGAAGCCATGGTGCAAGAAGTG
CTGAGTAAGATTCAGCATGGGCACACAATCATTTCAGTTGCTCATCGCTTGTCTACGGTC
AGAGCTGCAGATACCATCATTGGTTTTGAACATGGCACTGCAGTGGAAAGAGGGACCCAT
GAAGAATTACTGGAAAGGAAAGGTGTTTACTTCACTCTAGTGACTTTGCAAAGCCAGGGA
AATCAAGCTCTTAATGAAGAGGACATAAAGGATGCAACTGAAGATGACATGCTTGCGAGG
ACCTTTAGCAGAGGGAGCTACCAGGATAGTTTAAGGGCTTCCATCCGGCAACGCTCCAAG
TCTCAGCTTTCTTACCTGGTGCACGAACCTCCATTAGCTGTTGTAGATCATAAGTCTACC
TATGAAGAAGATAGAAAGGACAAGGACATTCCTGTGCAGGAAGAAGTTGAACCTGCCCCA
GTTAGGAGGATTCTGAAATTCAGTGCTCCAGAATGGCCCTACATGCTGGTAGGGTCTGTG
GGTGCAGCTGTGAACGGGACAGTCACACCCTTGTATGCCTTTTTATTCAGCCAGATTCTT
GGGACTTTTTCAATTCCTGATAAAGAGGAACAAAGGTCACAGATCAATGGTGTGTGCCTA
CTTTTTGTAGCAATGGGCTGTGTATCTCTTTTCACCCAATTTCTACAGGGATATGCCTTT
GCTAAATCTGGGGAGCTCCTAACAAAAAGGCTACGTAAATTTGGTTTCAGGGCAATGCTG
GGGCAAGATATTGCCTGGTTTGATGACCTCAGAAATAGCCCTGGAGCATTGACAACAAGA
CTTGCTACAGATGCTTCCCAAGTTCAAGGGGCTGCCGGCTCTCAGATCGGGATGATAGTC
AATTCCTTCACTAACGTCACTGTGGCCATGATCATTGCCTTCTCCTTTAGCTGGAAGCTG
AGCCTGGTCATCTTGTGCTTCTTCCCCTTCTTGGCTTTATCAGGAGCCACACAGACCAGG
ATGTTGACAGGATTTGCCTCTCGAGATAAGCAGGCCCTGGAGATGGTGGGACAGATTACA
AATGAAGCCCTCAGTAACATCCGCACTGTTGCTGGAATTGGAAAGGAGAGGCGGTTCATT
GAAGCACTTGAGACTGAGCTGGAGAAGCCCTTCAAGACAGCCATTCAGAAAGCCAATATT
TACGGATTCTGCTTTGCCTTTGCCCAGTGCATCATGTTTATTGCGAATTCTGCTTCCTAC
AGATATGGAGGTTACTTAATCTCCAATGAGGGGCTCCATTTCAGCTATGTGTTCAGGGTG
ATCTCTGCAGTTGTACTGAGTGCAACAGCTCTTGGAAGAGCCTTCTCTTACACCCCAAGT
TATGCAAAAGCTAAAATATCAGCTGCACGCTTTTTTCAACTGCTGGACCGACAACCCCCA
ATCAGTGTATACAATACTGCAGGTGAAAAATGGGACAACTTCCAGGGGAAGATTGATTTT
GTTGATTGTAAATTTACATATCCTTCTCGACCTGACTCGCAAGTTCTGAATGGTCTCTCA
GTGTCGATTAGTCCAGGGCAGACACTGGCGTTTGTTGGGAGCAGTGGATGTGGCAAAAGC
ACTAGCATTCAGCTGTTGGAACGTTTCTATGATCCTGATCAAGGGAAGGTGATGATAGAT
GGTCATGACAGCAAAAAAGTAAATGTCCAGTTCCTCCGCTCAAACATTGGAATTGTTTCC
CAGGAACCAGTGTTGTTTGCCTGTAGCATAATGGACAATATCAAGTATGGAGACAACACC
AAAGAAATTCCCATGGAAAGAGTCATAGCAGCTGCAAAACAGGCTCAGCTGCATGATTTT
GTCATGTCACTCCCAGAGAAATATGAAACTAACGTTGGGTCCCAGGGGTCTCAACTCTCT
AGAGGGGAGAAACAACGCATTGCTATTGCTCGGGCCATTGTACGAGATCCTAAAATCTTG
CTACTAGATGAAGCCACTTCTGCCTTAGACACAGAAAGTGAAAAGACGGTGCAGGTTGCT
CTAGACAAAGCCAGAGAGGGTCGGACCTGCATTGTCATTGCCCATCGCTTGTCCACCATC
CAGAACGCGGATATCATTGCTGTCATGGCACAGGGGGTGGTGATTGAAAAGGGGACCCAT
GAAGAACTGATGGCCCAAAAAGGAGCCTACTACAAACTAGTCACCACTGGATCCCCCATC
AGTTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical part of cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intercellular canaliculus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>bile acid-exporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>canalicular bile acid transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-exporting ATPase activity, phosphorylative mechanism</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>canalicular bile acid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>